3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
| Title | Journal |
|---|---|
| Effect of acetylcholinesterase inhibitors donepezil and rivastigmine on the activity and expression of cyclooxygenases in a model of the inflammatory action of fluoride on macrophages obtained from THP-1 monocytes. | Toxicology 20180801 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Rivastigmine for vascular cognitive impairment. | The Cochrane database of systematic reviews 20130531 |
| Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. | Chemico-biological interactions 20130325 |
| Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. | Journal of medicinal chemistry 20121108 |
| Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease. | Bioorganic & medicinal chemistry 20121101 |
| A rivastigmine-precipitated manic episode in a patient with Alzheimer-type dementia. | International psychogeriatrics 20121001 |
| Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. | Current neurology and neuroscience reports 20121001 |
| Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. | Drug safety 20121001 |
| Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer's disease. | Journal of the American Geriatrics Society 20121001 |
| Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment. | Endocrine, metabolic & immune disorders drug targets 20120901 |
| Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial. | International journal of geriatric psychiatry 20120901 |
| Treatment of delirium following cardiac surgery. | Journal of cardiac surgery 20120901 |
| Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. | Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 20120901 |
| Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120830 |
| Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking. | Molecules (Basel, Switzerland) 20120824 |
| Acetylcholinesterase inhibitors: a patent review (2008 - present). | Expert opinion on therapeutic patents 20120801 |
| Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. | The Lancet. Neurology 20120801 |
| Amphiphilic polyaspartamide copolymer-based micelles for rivastigmine delivery to neuronal cells. | Drug delivery 20120801 |
| Clinical practice with antidementia drugs in a geriatric clinic. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20120801 |
| Re-engineering aryl methylcarbamates to confer high selectivity for inhibition of Anopheles gambiae versus human acetylcholinesterase. | Bioorganic & medicinal chemistry letters 20120715 |
| Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats. | Human & experimental toxicology 20120701 |
| The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine transport through the blood-brain barrier. | Neurochemical research 20120701 |
| Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120701 |
| Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120701 |
| Effect of some medicinal plant extracts on the oxidative stress status in Alzheimer's disease induced in rats. | European review for medical and pharmacological sciences 20120701 |
| Steroidal alkaloids from Holarrhena antidysenterica as acetylcholinesterase inhibitors and the investigation for structure-activity relationships. | Life sciences 20120614 |
| Assessing health-related quality-of-life changes in informal caregivers: an evaluation in parents of children with major congenital anomalies. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20120601 |
| Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study. | Journal of clinical psychopharmacology 20120601 |
| Alzheimer's disease: early diagnosis and treatment. | Hong Kong medical journal = Xianggang yi xue za zhi 20120601 |
| Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120502 |
| Estimation of financial burden due to oversupply of medications for chronic diseases. | Asia-Pacific journal of public health 20120501 |
| The ethics of elective psychopharmacology. | The international journal of neuropsychopharmacology 20120501 |
| Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation. | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20120501 |
| Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS. | Journal of pharmaceutical and biomedical analysis 20120501 |
| Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease? | American journal of Alzheimer's disease and other dementias 20120501 |
| Rivastigmine reduces 'Likely to use methamphetamine' in methamphetamine-dependent volunteers. | Progress in neuro-psychopharmacology & biological psychiatry 20120427 |
| Hallucinations treated with rivastigmine in Creutzfeldt-Jakob disease. | Fundamental & clinical pharmacology 20120401 |
| New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. | British journal of clinical pharmacology 20120401 |
| Genetic screening and democracy: lessons from debating genetic screening criteria in the Netherlands. | Journal of community genetics 20120401 |
| Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. | Pharmacology & therapeutics 20120401 |
| Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20120401 |
| Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. | The Annals of pharmacotherapy 20120401 |
| Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. | Drugs of today (Barcelona, Spain : 1998) 20120401 |
| Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. | The Cochrane database of systematic reviews 20120314 |
| Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats. | Current Alzheimer research 20120301 |
| Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. | Cold Spring Harbor perspectives in medicine 20120301 |
| aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease. | The journal of nutrition, health & aging 20120201 |
| Development of a capillary electrophoresis-mass spectrometry method for the determination of rivastigmine in human plasma--optimization of the limits of detection and quantitation. | Electrophoresis 20120201 |
| A fatal outcome after unintentional overdosing of rivastigmine patches. | Current drug safety 20120201 |
| Acetylcholinesterase inhibitors for schizophrenia. | The Cochrane database of systematic reviews 20120118 |
| Advances in functional neuroimaging in dementias and potential pitfalls. | Neurology international 20120109 |
| Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient. | Journal of pharmaceutical and biomedical analysis 20120105 |
| Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease. | International journal of Alzheimer's disease 20120101 |
| New acetylcholinesterase inhibitors for Alzheimer's disease. | International journal of Alzheimer's disease 20120101 |
| [Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120101 |
| Systematic review on the efficacy and safety of herbal medicines for vascular dementia. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. | Expert review of neurotherapeutics 20120101 |
| Tinnitus: network pathophysiology-network pharmacology. | Frontiers in systems neuroscience 20120101 |
| Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients. | Parkinson's disease 20120101 |
| Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. | BMC neurology 20120101 |
| Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. | Frontiers in neurology 20120101 |
| Effect of a CNS-Sensitive Anticholinesterase Methane Sulfonyl Fluoride on Hippocampal Acetylcholine Release in Freely Moving Rats. | Advances in pharmacological sciences 20120101 |
| Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. | Current Alzheimer research 20120101 |
| Ethnobotanical treatment strategies against Alzheimer's disease. | Current Alzheimer research 20120101 |
| Evaluation of the effect of Ferula asafoetida Linn. gum extract on learning and memory in Wistar rats. | Indian journal of pharmacology 20120101 |
| Pisa syndrome secondary to rivastigmine: a case report. | La Clinica terapeutica 20120101 |
| Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. | PloS one 20120101 |
| Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems. | PloS one 20120101 |
| Metal chaperones: a holistic approach to the treatment of Alzheimer's disease. | Frontiers in psychiatry 20120101 |
| Does using a femoral nerve block for total knee replacement decrease postoperative delirium? | BMC anesthesiology 20120101 |
| Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors. | Journal of Alzheimer's disease : JAD 20120101 |
| Effect of toki-shakuyaku-san on regional cerebral blood flow in patients with mild cognitive impairment and Alzheimer's disease. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| β-Secretases, Alzheimer's Disease, and Down Syndrome. | Current gerontology and geriatrics research 20120101 |
| Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. | International journal of Alzheimer's disease 20120101 |
| Alzheimer's disease and the amyloid cascade hypothesis: a critical review. | International journal of Alzheimer's disease 20120101 |
| Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action. | International journal of Alzheimer's disease 20120101 |
| Alzheimer's disease: a clinical practice-oriented review. | Frontiers in neurology 20120101 |
| Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. | Neuropsychiatric disease and treatment 20120101 |
| The 'brain-skin connection' in protein misfolding and amyloid deposits: embryological, pathophysiological, and therapeutic common grounds? | Frontiers in neurology 20120101 |
| Novel therapeutics in Alzheimer's disease. | International journal of Alzheimer's disease 20120101 |
| The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. | Health technology assessment (Winchester, England) 20120101 |
| Age-related neurodegeneration and memory loss in down syndrome. | Current gerontology and geriatrics research 20120101 |
| Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. | PloS one 20120101 |
| [New anti-AD drugs--their possibilities and issues]. | Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101 |
| [Strategy and perspectives for development of Alzheimer disease-modifying drugs]. | Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20120101 |
| Behavioral and psychological symptoms of dementia. | Frontiers in neurology 20120101 |
| Exercise and early-onset Alzheimer's disease: theoretical considerations. | Dementia and geriatric cognitive disorders extra 20120101 |
| Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study. | International journal of medical sciences 20120101 |
| The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. | PloS one 20120101 |
| Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. | International journal of nanomedicine 20120101 |
| CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. | Dementia and geriatric cognitive disorders extra 20120101 |
| Use of cognitive enhancers for mild cognitive impairment: protocol for a systematic review and network meta-analysis. | Systematic reviews 20120101 |
| Cognitive dysfunction in multiple sclerosis. | Frontiers in neurology 20120101 |
| Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. | Frontiers in neurology 20120101 |
| Wading pools, fading memories-place navigation in transgenic mouse models of Alzheimer's disease. | Frontiers in aging neuroscience 20120101 |
| Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. | International journal of Alzheimer's disease 20120101 |
| Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia. | Depression research and treatment 20120101 |
| The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. | Parkinson's disease 20120101 |
| Efficacy of cognitive enhancers for Alzheimer's disease: protocol for a systematic review and network meta-analysis. | Systematic reviews 20120101 |
| Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. | Clinical neuropharmacology 20120101 |
| Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients. | Journal of Alzheimer's disease : JAD 20120101 |
| Transdermal donepezil on the treatment of Alzheimer's disease. | Neuropsychiatric disease and treatment 20120101 |
| Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and amyloid precursor protein (AβPP) expression in rat brain. | Indian journal of pharmacology 20120101 |
| Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. | Journal of medicinal chemistry 20111222 |
| Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. | Progress in neuro-psychopharmacology & biological psychiatry 20111201 |
| Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. | The British journal of psychiatry : the journal of mental science 20111201 |
| Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. | International journal of geriatric psychiatry 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Sundown syndrome in persons with dementia: an update. | Psychiatry investigation 20111201 |
| Alzheimer's dementia: current data review. | Collegium antropologicum 20111201 |
| The neurotrophins and their role in Alzheimer's disease. | Current neuropharmacology 20111201 |
| [Rivastigmine]. | Nihon rinsho. Japanese journal of clinical medicine 20111201 |
| Preparation and evaluation of injectable sustained-release microspheres of rivastigmine. | Journal of controlled release : official journal of the Controlled Release Society 20111130 |
| Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. | Behavioural brain research 20111120 |
| Expressing findings from meta-analyses of continuous outcomes in terms of risks. | Statistics in medicine 20111110 |
| Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task. | Current Alzheimer research 20111101 |
| BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. | European journal of clinical pharmacology 20111101 |
| The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. | Multiple sclerosis (Houndmills, Basingstoke, England) 20111101 |
| Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20111101 |
| Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. | European journal of medicinal chemistry 20111101 |
| Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type. | Drugs & aging 20111101 |
| Effective pharmacological management of Alzheimer's disease. | The American journal of managed care 20111101 |
| Residual vectors for Alzheimer disease diagnosis and prognostication. | Brain and behavior 20111101 |
| Current and emerging drug treatment options for Alzheimer's disease: a systematic review. | Drugs 20111022 |
| Pharmacologic treatment for memory disorder in multiple sclerosis. | The Cochrane database of systematic reviews 20111005 |
| Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111001 |
| Synthesis and biological evaluation of novel N,N'-bis-methylenedioxybenzyl-alkylenediamines as bivalent anti-Alzheimer disease ligands. | Journal of enzyme inhibition and medicinal chemistry 20111001 |
| Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. | CNS neuroscience & therapeutics 20111001 |
| Treatment of dementia with Lewy bodies and Parkinson's disease dementia. | Drugs & aging 20111001 |
| Sepsis-associated encephalopathy: not just delirium. | Clinics (Sao Paulo, Brazil) 20111001 |
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20111001 |
| Cholinesterase inhibitor initiation in hospital setting. | Journal of the American Geriatrics Society 20111001 |
| 1,3-substituted imidazolidine-2,4,5-triones: synthesis and inhibition of cholinergic enzymes. | Molecules (Basel, Switzerland) 20110905 |
| Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. | Pharmacology, biochemistry, and behavior 20110901 |
| Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. | Pharmacology, biochemistry, and behavior 20110901 |
| Cholinergic imbalance in the multiple sclerosis hippocampus. | Acta neuropathologica 20110901 |
| Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. | Expert opinion on investigational drugs 20110901 |
| Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20110901 |
| Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. | American journal of Alzheimer's disease and other dementias 20110901 |
| Addressing neuropsychiatric disturbances during rehabilitation after traumatic brain injury: current and future methods. | Dialogues in clinical neuroscience 20110901 |
| Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. | Journal of clinical neurology (Seoul, Korea) 20110901 |
| Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. | Journal of psychopharmacology (Oxford, England) 20110801 |
| A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20110801 |
| Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors. | Bioorganic chemistry 20110801 |
| [Newly approved drugs for Alzheimer disease: effectiveness and limitation]. | Brain and nerve = Shinkei kenkyu no shinpo 20110801 |
| New drugs for Alzheimer's disease in Japan. | Psychiatry and clinical neurosciences 20110801 |
| Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs. | Die Pharmazie 20110801 |
| Vascular dementia. | Chonnam medical journal 20110801 |
| A case of rivastigmine toxicity caused by transdermal patch. | The American journal of emergency medicine 20110701 |
| Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population. | Geriatrics & gerontology international 20110701 |
| New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. | Drug development and industrial pharmacy 20110701 |
| [Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales]. | Psychiatrische Praxis 20110701 |
| [Prescription differences of dementia drugs in urban and rural areas in Germany]. | Psychiatrische Praxis 20110701 |
| Species independence in brain tissue binding using brain homogenates. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. | Current medical research and opinion 20110701 |
| Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. | Nature chemical biology 20110701 |
| Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. | CNS drugs 20110701 |
| A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. | International journal of clinical practice 20110701 |
| Auditory object cognition in dementia. | Neuropsychologia 20110701 |
| Combination therapy for Alzheimer's disease. | Drugs & aging 20110701 |
| Rivastigmine associated hyponatremia in an older patient with Alzheimer's disease. | Journal of the American Geriatrics Society 20110701 |
| Psychosis in Parkinson's disease. | Annals of Indian Academy of Neurology 20110701 |
| Dementia in parkinsonism. | Annals of Indian Academy of Neurology 20110701 |
| [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. | Yao xue xue bao = Acta pharmaceutica Sinica 20110701 |
| Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. | Drugs 20110618 |
| Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. | Neurologia (Barcelona, Spain) 20110601 |
| A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment. | Psychopharmacology 20110601 |
| Rivastigmine reverses aluminum-induced behavioral changes in rats. | European journal of pharmacology 20110601 |
| Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. | European journal of medicinal chemistry 20110601 |
| First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine? | American journal of clinical dermatology 20110601 |
| The role of phytochemicals in the treatment and prevention of dementia. | Drugs & aging 20110601 |
| Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. | International journal of geriatric psychiatry 20110501 |
| Drug delivery strategies for Alzheimer's disease treatment. | Expert opinion on drug delivery 20110501 |
| Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire. | The journal of nutrition, health & aging 20110501 |
| Alternative drug therapies for dementia. | Journal of psychosocial nursing and mental health services 20110501 |
| Analgesic and antineuropathic drugs acting through central cholinergic mechanisms. | Recent patents on CNS drug discovery 20110501 |
| Rivastigmine patches: fatal overdoses. | Prescrire international 20110501 |
| Psychosis in Parkinson's disease: therapeutic options. | Drugs of today (Barcelona, Spain : 1998) 20110501 |
| Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease. | Therapeutic delivery 20110501 |
| Switching cholinesterase inhibitors in older adults with dementia. | International psychogeriatrics 20110401 |
| Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. | International journal of clinical practice 20110401 |
| Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. | International journal of geriatric psychiatry 20110401 |
| Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring. | Therapeutic drug monitoring 20110401 |
| Dual inhibition: a novel promising pharmacological approach for different disease conditions. | The Journal of pharmacy and pharmacology 20110401 |
| Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20110401 |
| Simultaneous determination of nine acetylcholinesterase inhibitors using micellar electrokinetic chromatography. | Journal of chromatographic science 20110401 |
| [Delirium in the elderly]. | Deutsche medizinische Wochenschrift (1946) 20110401 |
| Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. | Prescrire international 20110401 |
| Physical activity attenuates neuropsychiatric disturbances and caregiver burden in patients with dementia. | Clinics (Sao Paulo, Brazil) 20110401 |
| Cholinesterase inhibitor treatment in patients with delirium. | Lancet (London, England) 20110312 |
| Cholinesterase inhibitor treatment in patients with delirium. | Lancet (London, England) 20110312 |
| Cholinesterase inhibitor treatment in patients with delirium. | Lancet (London, England) 20110312 |
| Cholinesterase inhibitor treatment in patients with delirium. | Lancet (London, England) 20110312 |
| Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS. | Biomedical chromatography : BMC 20110301 |
| Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. | Current Alzheimer research 20110301 |
| Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability. | International journal of geriatric psychiatry 20110301 |
| Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy. | CNS drugs 20110301 |
| Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic. | The neurologist 20110301 |
| Alzheimer's drug proves ineffective for delirium. | The Harvard mental health letter 20110301 |
| MAO-inhibitors in Parkinson's Disease. | Experimental neurobiology 20110301 |
| Acetylcholine and chronic vasculopathy in rat renal allografts. | Transplantation 20110215 |
| Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. | The Gerontologist 20110201 |
| Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. | American journal of Alzheimer's disease and other dementias 20110201 |
| Clinical problems in the hospitalized Parkinson's disease patient: systematic review. | Movement disorders : official journal of the Movement Disorder Society 20110201 |
| Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110201 |
| Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study. | Croatian medical journal 20110201 |
| Therapeutic benefit of Yangxue Qingnao Granule on cognitive impairment induced by chronic cerebral hypoperfusion in rats. | Chinese journal of integrative medicine 20110201 |
| Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory. | Deutsches Arzteblatt international 20110201 |
| [Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences]. | Medizinische Monatsschrift fur Pharmazeuten 20110201 |
| Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine. | Behavioural pharmacology 20110201 |
| [Pharmacovigilance update]. | Revue medicale suisse 20110112 |
| A systematic review of single chinese herbs for Alzheimer's disease treatment. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Protective Effects of Rosa damascena and Its Active Constituent on Aβ(25-35)-Induced Neuritic Atrophy. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Cyproterone to treat aggressivity in dementia: a clinical case and systematic review. | Journal of psychopharmacology (Oxford, England) 20110101 |
| Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. | Alzheimer disease and associated disorders 20110101 |
| Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. | Alzheimer disease and associated disorders 20110101 |
| Cognitive enhancement by drugs in health and disease. | Trends in cognitive sciences 20110101 |
| Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. | Brain : a journal of neurology 20110101 |
| [Somatoform disorder or neurological syndrome? Complex mental and movement disorder and autonomic dysfunction in a 65-year-old patient - Case 1/2011]. | Deutsche medizinische Wochenschrift (1946) 20110101 |
| The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. | Journal of biomedical science 20110101 |
| Antidepressants modulate intracellular amyloid peptide species in N2a neuroblastoma cells. | Journal of Alzheimer's disease : JAD 20110101 |
| An atypical cutaneous reaction to rivastigmine transdermal patch. | Journal of allergy 20110101 |
| Neuroimaging in dementia. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20110101 |
| Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. | BMC neurology 20110101 |
| Effectiveness of a structured education reminiscence-based programme for staff on the quality of life of residents with dementia in long-stay units: a study protocol for a cluster randomised trial. | Trials 20110101 |
| Tackling dementia in patients with Parkinson's disease. | The Practitioner 20110101 |
| New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. | Parkinson's disease 20110101 |
| Cognitive-enhancing effects of polygalasaponin hydrolysate in aβ(25-35)-induced amnesic mice. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. | International journal of nanomedicine 20110101 |
| Rehabilitating a brain with Alzheimer's: a proposal. | Clinical interventions in aging 20110101 |
| Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. | Dementia and geriatric cognitive disorders 20110101 |
| Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. | Alzheimer's research & therapy 20110101 |
| Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia. | Chinese medicine 20110101 |
| Function and comorbidities of apolipoprotein e in Alzheimer's disease. | International journal of Alzheimer's disease 20110101 |
| Memory loss, behavioral changes, and slurred speech in a 49-year-old man. | Frontiers in neurology 20110101 |
| Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. | Neuropsychiatric disease and treatment 20110101 |
| Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. | BMC neurology 20110101 |
| Clinical features and multidisciplinary approaches to dementia care. | Journal of multidisciplinary healthcare 20110101 |
| Effect of plant extracts on Alzheimer's disease: An insight into therapeutic avenues. | Journal of neurosciences in rural practice 20110101 |
| Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease. | Alzheimer's research & therapy 20110101 |
| The 'aged garlic extract:' (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD). | Current medicinal chemistry 20110101 |
| Micro Electromechanical Systems (MEMS) Based Microfluidic Devices for Biomedical Applications. | International journal of molecular sciences 20110101 |
| Cognition and Lewy body disease. | Actas espanolas de psiquiatria 20110101 |
| Alzheimer's disease, anesthesia and the cholinergic system. | Journal of anaesthesiology, clinical pharmacology 20110101 |
| Sick sinus syndrome with Alzheimer's disease for bilateral hernia repair. | Journal of anaesthesiology, clinical pharmacology 20110101 |
| Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. | Frontiers in systems neuroscience 20110101 |
| Predictors of long-term cognitive outcome in Alzheimer's disease. | Alzheimer's research & therapy 20110101 |
| Cutaneous reactions to transdermal therapeutic systems. | Dermatitis : contact, atopic, occupational, drug 20110101 |
| Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. | PloS one 20110101 |
| Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians. | BMC neurology 20110101 |
| Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease. | Dementia and geriatric cognitive disorders 20110101 |
| Overactive bladder: the importance of tailoring treatment to the individual patient. | Journal of multidisciplinary healthcare 20110101 |
| Alzheimer's disease: emerging trends in small molecule therapies. | Current medicinal chemistry 20110101 |
| Age-related white matter changes. | Journal of aging research 20110101 |
| Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study. | Critical care (London, England) 20110101 |
| Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. | PloS one 20110101 |
| Examining brain-cognition effects of ginkgo biloba extract: brain activation in the left temporal and left prefrontal cortex in an object working memory task. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706. | Frontiers in molecular neuroscience 20110101 |
| Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis. | The primary care companion for CNS disorders 20110101 |
| Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. | BMC health services research 20110101 |
| A clinical update on delirium: from early recognition to effective management. | Nursing research and practice 20110101 |
| Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment. | Alzheimer's research & therapy 20110101 |
| Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting. | Neuropsychiatric disease and treatment 20110101 |
| Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. | Trials 20110101 |
| Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study. | BMJ open 20110101 |
| In vivo investigation of the neuroprotective property of Convolvulus pluricaulis in scopolamine-induced cognitive impairments in Wistar rats. | Indian journal of pharmacology 20110101 |
| Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation. | ClinicoEconomics and outcomes research : CEOR 20110101 |
| Hippocampal microbleed on a post-mortem t(2)∗-weighted gradient-echo 7.0-tesla magnetic resonance imaging? | Case reports in neurology 20110101 |
| Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. | Alzheimer's research & therapy 20110101 |
| Targeting acetylcholinesterase: identification of chemical leads by high throughput screening, structure determination and molecular modeling. | PloS one 20110101 |
| Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. | BMC psychiatry 20110101 |
| Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease. | Alzheimer's research & therapy 20110101 |
| The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease. | Dementia and geriatric cognitive disorders extra 20110101 |
| A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. | Dementia and geriatric cognitive disorders extra 20110101 |
| Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients. | Dementia and geriatric cognitive disorders extra 20110101 |
| Neural Correlates of Stroop Performance in Alzheimer's Disease: A FDG-PET Study. | Dementia and geriatric cognitive disorders extra 20110101 |
| The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis. | Dementia and geriatric cognitive disorders extra 20110101 |
| Huperzine induces alteration in oxidative balance and antioxidants in a guinea pig model. | Neuro endocrinology letters 20110101 |
| Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. | Oxidative medicine and cellular longevity 20110101 |
| Dementia after DBS Surgery: A Case Report and Literature Review. | Parkinson's disease 20110101 |
| Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). | Journal of drug delivery 20110101 |
| ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice. | Journal of biomedicine & biotechnology 20110101 |
| Acetylcholine and memory-enhancing activity of Ficus racemosa bark. | Pharmacognosy research 20110101 |
| Evaluation of diet and life style in etiopathogenesis of senile dementia: A survey study. | Ayu 20110101 |
| Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. | The primary care companion for CNS disorders 20110101 |
| Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding? | Dementia and geriatric cognitive disorders extra 20110101 |
| Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report. | Iranian journal of psychiatry 20110101 |
| Identification of non-alkaloid acetylcholinesterase inhibitors from Ferulago campestris (Besser) Grecescu (Apiaceae). | Fitoterapia 20101201 |
| Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds. | The Journal of pharmacology and experimental therapeutics 20101201 |
| Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. | Cardiovascular toxicology 20101201 |
| Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors. | European journal of medicinal chemistry 20101201 |
| Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. | CNS neuroscience & therapeutics 20101201 |
| Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. | Neurochemical research 20101201 |
| Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. | American journal of Alzheimer's disease and other dementias 20101201 |
| Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up. | Journal of child and adolescent psychopharmacology 20101201 |
| Alzheimer's disease: aging, insomnia and epigenetics. | Taiwanese journal of obstetrics & gynecology 20101201 |
| Cholinergic crisis after rodenticide poisoning. | The western journal of emergency medicine 20101201 |
| Vascular cognitive impairment: Current concepts and Indian perspective. | Annals of Indian Academy of Neurology 20101201 |
| Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings. | Journal of toxicologic pathology 20101201 |
| Delirium treatment: an unmet challenge. | Lancet (London, England) 20101127 |
| Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. | Lancet (London, England) 20101127 |
| Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities. | ACS chemical neuroscience 20101117 |
| The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. | CNS drugs 20101101 |
| Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. | Drugs & aging 20101101 |
| Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20101001 |
| The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. | Current medical research and opinion 20101001 |
| Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat. | Learning & memory (Cold Spring Harbor, N.Y.) 20101001 |
| Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. | Deutsches Arzteblatt international 20101001 |
| [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness]. | MMW Fortschritte der Medizin 20100916 |
| Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. | Journal of medicinal chemistry 20100909 |
| Current treatment options for people with Alzheimer's disease in Croatia. | Chemico-biological interactions 20100906 |
| Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro. | Chemico-biological interactions 20100906 |
| Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells. | Alzheimer's & dementia : the journal of the Alzheimer's Association 20100901 |
| Treatment of Irritability in Huntington's Disease. | Current treatment options in neurology 20100901 |
| Management of mixed dementia. | Drugs & aging 20100901 |
| Current treatments for patients with Alzheimer disease. | The Journal of the American Osteopathic Association 20100901 |
| Modern care for patients with Alzheimer disease: rationale for early intervention. | The Journal of the American Osteopathic Association 20100901 |
| Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. | Dialogues in clinical neuroscience 20100901 |
| [Treatment of Alzheimer's disease: the current situation?]. | Revue medicale de Bruxelles 20100901 |
| Chemoenzymatic asymmetric total synthesis of (S)-Rivastigmine using omega-transaminases. | Chemical communications (Cambridge, England) 20100814 |
| Management of inappropriate sexual behaviors in dementia: a literature review. | International psychogeriatrics 20100801 |
| Rivastigmine in the treatment of delirium in older people: a pilot study. | International psychogeriatrics 20100801 |
| Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. | CNS neuroscience & therapeutics 20100801 |
| Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. | American journal of Alzheimer's disease and other dementias 20100801 |
| Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease. | Biomaterials 20100801 |
| Predictors of adherence among Alzheimer's disease patients receiving oral therapy. | Current medical research and opinion 20100801 |
| Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. | Drugs & aging 20100801 |
| Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. | Journal of medicinal chemistry 20100722 |
| Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization. | Allergy 20100701 |
| [S3 guidelines on dementia. Symptomatic therapy of dementia]. | Der Nervenarzt 20100701 |
| [Development of new drugs for Alzheimer's disease]. | Brain and nerve = Shinkei kenkyu no shinpo 20100701 |
| Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. | Pharmacological research 20100601 |
| Entering and exiting the Medicare part D coverage gap: role of comorbidities and demographics. | Journal of general internal medicine 20100601 |
| Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. | American journal of Alzheimer's disease and other dementias 20100601 |
| Altered neural cholinergic receptor systems in cocaine-addicted subjects. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100601 |
| [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences]. | Psychologie & neuropsychiatrie du vieillissement 20100601 |
| How do we treat people with dementia in Croatia. | Psychiatria Danubina 20100601 |
| [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. | Tijdschrift voor gerontologie en geriatrie 20100601 |
| Antiamnesic effect of stevioside in scopolamine-treated rats. | Indian journal of pharmacology 20100601 |
| Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents. | Experimental neurobiology 20100601 |
| Study of rivastigmine for delirium in intensive care is stopped after deaths. | BMJ (Clinical research ed.) 20100528 |
| Chemoenzymatic synthesis of rivastigmine via dynamic kinetic resolution as a key step. | The Journal of organic chemistry 20100507 |
| Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. | Journal of neurology, neurosurgery, and psychiatry 20100501 |
| Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). | Current medical research and opinion 20100501 |
| Anticholinesterase duration in the Australian veteran population. | The Australian and New Zealand journal of psychiatry 20100501 |
| Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product. | Drug testing and analysis 20100501 |
| Identification and characterization of new impurities in rivastigmine. | Die Pharmazie 20100501 |
| [Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease]. | Neurologia (Barcelona, Spain) 20100501 |
| Agrypnia with nocturnal confusional behaviors in dementia with Lewy bodies: immediate efficacy of rivastigmine. | Movement disorders : official journal of the Movement Disorder Society 20100415 |
| Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease. | Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20100415 |
| WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. | Behavioural brain research 20100402 |
| Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). | International journal of geriatric psychiatry 20100401 |
| A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. | Acta neurologica Scandinavica 20100401 |
| Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. | International journal of clinical practice 20100401 |
| Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. | CNS drugs 20100401 |
| Cholinesterase inhibitors and delirium after cardiac surgery. | Critical care medicine 20100401 |
| Drug therapies for cognitive impairment and dementia. | Journal of psychosocial nursing and mental health services 20100401 |
| [Development of anti-Alzheimer's disease drug based on beta-amyloid hypothesis]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20100401 |
| Increasing rational use of cholinesterase inhibitors for Alzheimer's disease in Brazil: public health strategy combining guideline with peer-review of prescriptions. | International journal of technology assessment in health care 20100401 |
| Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. | British journal of clinical pharmacology 20100401 |
| Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface? | International journal of clinical practice 20100401 |
| Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection: a review. | International journal of environmental research and public health 20100401 |
| Calcium signaling and neurodegeneration. | Acta naturae 20100401 |
| Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. | Seizure 20100301 |
| Prescribing of drugs for Alzheimer's disease: a South African database analysis. | International psychogeriatrics 20100301 |
| Galantamine for Alzheimer's disease. | Expert opinion on drug metabolism & toxicology 20100301 |
| Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. | Chemical & pharmaceutical bulletin 20100301 |
| Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20100301 |
| Update on the pharmacological treatment of Alzheimer's disease. | Current neuropharmacology 20100301 |
| Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. | Journal of medicinal chemistry 20100211 |
| Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. | International psychogeriatrics 20100201 |
| A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. | Journal of neurochemistry 20100201 |
| A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. | Current medical research and opinion 20100201 |
| Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. | CNS drugs 20100201 |
| Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. | Current Alzheimer research 20100201 |
| Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. | International clinical psychopharmacology 20100101 |
| Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. | Clinical neuropharmacology 20100101 |
| Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. | Clinical drug investigation 20100101 |
| Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. | Expert opinion on drug safety 20100101 |
| Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. | CNS drugs 20100101 |
| Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. | CNS neuroscience & therapeutics 20100101 |
| Cognitive enhancement as a pharmacotherapy target for stimulant addiction. | Addiction (Abingdon, England) 20100101 |
| Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. | International journal of clinical practice 20100101 |
| Altered levels of acetylcholinesterase in Alzheimer plasma. | PloS one 20100101 |
| Improvement of cognitive dysfunction with high-dose rivastigmine. | Psychosomatics 20100101 |
| Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. | Alzheimer's & dementia : the journal of the Alzheimer's Association 20100101 |
| Neurochemical basis for symptomatic treatment of Alzheimer's disease. | Neuropharmacology 20100101 |
| Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. | BMC neurology 20100101 |
| Frontotemporal dementia and pharmacologic interventions. | The Journal of neuropsychiatry and clinical neurosciences 20100101 |
| Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. | Journal of Alzheimer's disease : JAD 20100101 |
| Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. | Clinical interventions in aging 20100101 |
| Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). | Die Pharmazie 20100101 |
| Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. | Particle and fibre toxicology 20100101 |
| Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT4 receptor knock-out mice. | PloS one 20100101 |
| Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. | Molecular neurodegeneration 20100101 |
| Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. | BMC geriatrics 20100101 |
| Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. | Dementia and geriatric cognitive disorders 20100101 |
| New lobane and cembrane diterpenes from two comorian soft corals. | Marine drugs 20100101 |
| Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model. | BMC medical informatics and decision making 20100101 |
| Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. | Dementia and geriatric cognitive disorders 20100101 |
| Cobalamin deficiency, hyperhomocysteinemia, and dementia. | Neuropsychiatric disease and treatment 20100101 |
| Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. | Dementia and geriatric cognitive disorders 20100101 |
| Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? | Alzheimer's research & therapy 20100101 |
| Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. | Journal of Alzheimer's disease : JAD 20100101 |
| Novel therapeutic drugs for neuropsychiatric disorders. | The open medicinal chemistry journal 20100101 |
| Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. | PloS one 20100101 |
| Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals. | BMC health services research 20100101 |
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | Frontiers in aging neuroscience 20100101 |
| Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report. | BMC psychiatry 20100101 |
| Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature. | BMC psychiatry 20100101 |
| Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment? | International journal of Alzheimer's disease 20100101 |
| Neurovascular coupling in Parkinson's disease patients: effects of dementia and acetylcholinesterase inhibitor treatment. | Journal of Alzheimer's disease : JAD 20100101 |
| Circadian rhythm disturbances in patients with Alzheimer's disease: a review. | International journal of Alzheimer's disease 20100101 |
| Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease. | Cardiovascular psychiatry and neurology 20100101 |
| Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. | BMC neurology 20100101 |
| A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease. | Alzheimer's research & therapy 20100101 |
| New approaches in the management of multiple sclerosis. | Drug design, development and therapy 20100101 |
| Huntington's disease: a clinical review. | Orphanet journal of rare diseases 20100101 |
| Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. | Alzheimer's research & therapy 20100101 |
| [Rivastigmine in the treatment of dementia: from the symptomatic effect to neuroprotection]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101 |
| Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. | Primary care companion to the Journal of clinical psychiatry 20100101 |
| [Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101 |
| The geriatric population and psychiatric medication. | Mens sana monographs 20100101 |
| Treatment of advanced Parkinson's disease. | Parkinson's disease 20100101 |
| An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke. | Functional neurology 20100101 |
| [Efficacy and safety of rivastigmine (exelon) in the confusion syndrome in the acute phase of ischemic stroke]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101 |
| [Cholinesterase inhibitors for treating dementia. Review]. | Vertex (Buenos Aires, Argentina) 20100101 |
| Dementia. | BMJ clinical evidence 20100101 |
| Traditional used Plants against Cognitive Decline and Alzheimer Disease. | Frontiers in pharmacology 20100101 |
| Phospholipase C beta 4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20091209 |
| Neurovascular coupling in Alzheimer patients: effect of acetylcholine-esterase inhibitors. | Neurobiology of aging 20091201 |
| International price comparisons of Alzheimer's drugs: a way to close the affordability gap. | International psychogeriatrics 20091201 |
| Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. | The Journal of pharmacology and experimental therapeutics 20091201 |
| Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine. | Journal of neural transmission (Vienna, Austria : 1996) 20091201 |
| Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study. | Journal of clinical pharmacy and therapeutics 20091201 |
| Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. | Journal of the American Geriatrics Society 20091101 |
| Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer's. | Evidence-based mental health 20091101 |
| Hepatitis with cholestasis caused by rivastigmine transdermal patch. | The American journal of gastroenterology 20091101 |
| Packages of care for dementia in low- and middle-income countries. | PLoS medicine 20091101 |
| Can we do better in developing new drugs for Alzheimer's disease? | Alzheimer's & dementia : the journal of the Alzheimer's Association 20091101 |
| Alzheimer's disease: Seeing the signs early. | Journal of the American Academy of Nurse Practitioners 20091101 |
| Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20091101 |
| Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. | International psychogeriatrics 20091001 |
| Dorsolateral prefrontal cortex activity predicts responsiveness to cognitive-behavioral therapy in schizophrenia. | Biological psychiatry 20090915 |
| Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors. | Bioorganic & medicinal chemistry 20090915 |
| Rivastigmine reverses habituation memory impairment observed in sepsis survivor rats. | Shock (Augusta, Ga.) 20090901 |
| New potential AChE inhibitor candidates. | European journal of medicinal chemistry 20090901 |
| Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity. | Human & experimental toxicology 20090901 |
| Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. | PLoS medicine 20090901 |
| Cognitive impairment in Parkinson's disease without dementia: subtypes and influences of age. | Journal of clinical neurology (Seoul, Korea) 20090901 |
| [The possible value of diagnosing MCI-DLB and treatment options]. | Tijdschrift voor gerontologie en geriatrie 20090901 |
| Chemoenzymatic synthesis of rivastigmine based on lipase-catalyzed processes. | The Journal of organic chemistry 20090807 |
| Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis. | Journal of psychopharmacology (Oxford, England) 20090801 |
| Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. | European journal of pharmacology 20090801 |
| Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. | Pharmacogenetics and genomics 20090801 |
| Rivastigmine in Parkinson's disease dementia. | Expert opinion on drug metabolism & toxicology 20090801 |
| Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. | Current Alzheimer research 20090801 |
| Treatment of mild cognitive impairment (MCI). | Current Alzheimer research 20090801 |
| Cholinergic influence on memory stages: A study on scopolamine amnesic mice. | Indian journal of pharmacology 20090801 |
| Synthesis of novel purine nucleosides towards a selective inhibition of human butyrylcholinesterase. | Bioorganic & medicinal chemistry 20090715 |
| Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. | Journal of natural medicines 20090701 |
| Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. | The Lancet. Neurology 20090701 |
| Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. | Acta pharmacologica Sinica 20090701 |
| Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. | The neurologist 20090701 |
| Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. | Gender medicine 20090701 |
| [Mental handicap]. | Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie 20090701 |
| BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. | European journal of pharmacology 20090624 |
| Rational design of central selective acetylcholinesterase inhibitors by means of a 'bio-oxidisable prodrug' strategy. | Organic & biomolecular chemistry 20090621 |
| Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition. | Bioorganic & medicinal chemistry letters 20090615 |
| Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. | American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 20090605 |
| [Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)]. | Revista de neurologia 20090601 |
| A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught? | Brain injury 20090601 |
| Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. | Journal of medical economics 20090601 |
| [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease]. | Fortschritte der Neurologie-Psychiatrie 20090601 |
| Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. | International journal of molecular sciences 20090601 |
| Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. | Dialogues in clinical neuroscience 20090601 |
| Biological markers for early detection and pharmacological treatment of Alzheimer's disease. | Dialogues in clinical neuroscience 20090601 |
| Drug-induced sialorrhoea and excessive saliva accumulation. | Prescrire international 20090601 |
| [Progressive supranucleair palsy: acetylcholineeserase-inhibitor a possible therapy?]. | Tijdschrift voor gerontologie en geriatrie 20090601 |
| Treatment of Alzheimer's disease in the long-term-care setting. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090515 |
| Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery--a randomized controlled trial. | Critical care medicine 20090501 |
| Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia. | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20090501 |
| Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. | International journal of clinical practice 20090501 |
| [Frontotemporal dementia: neurotransmitter and clinical symptoms with focus on therapeutic targets]. | Fortschritte der Neurologie-Psychiatrie 20090501 |
| Rivastigmine reduces tobacco craving in alcohol-dependent smokers. | Pharmacopsychiatry 20090501 |
| Rivastigmine for Alzheimer's disease. | The Cochrane database of systematic reviews 20090415 |
| Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. | Journal of clinical pharmacology 20090401 |
| Cholinesterase inhibitors and beyond. | Current Alzheimer research 20090401 |
| [Treatment of degenerative dementia disorders--who should be treated?]. | Ugeskrift for laeger 20090302 |
| Long-term rivastigmine treatment in a routine clinical setting. | Acta neurologica Scandinavica 20090301 |
| Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. | Translational research : the journal of laboratory and clinical medicine 20090301 |
| Side effects of approved antidementives. | Psychiatria Danubina 20090301 |
| Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. | Neuroreport 20090218 |
| BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. | Movement disorders : official journal of the Movement Disorder Society 20090215 |
| Top cited papers in International Psychogeriatrics: 1. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. | International psychogeriatrics 20090201 |
| Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease. | Electrophoresis 20090201 |
| Long-term effects of rivastigmine capsules in patients with traumatic brain injury. | Brain injury 20090201 |
| Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. | Current Alzheimer research 20090201 |
| Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. | Journal of the American Geriatrics Society 20090201 |
| Rivastigmine patches: line extension. No therapeutic advantage and less convenient than capsules. | Prescrire international 20090201 |
| Rivastigmine for dementia in people with Down syndrome. | The Cochrane database of systematic reviews 20090121 |
| Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives. | European journal of medicinal chemistry 20090101 |
| Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. | The Biochemical journal 20090101 |
| Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. | Psychopharmacology 20090101 |
| Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101 |
| Cognitive impairment and preferences for current health. | Health and quality of life outcomes 20090101 |
| Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine. | The journal of nutrition, health & aging 20090101 |
| [The role of rivastigmine (exelon) in the treatment of consequences of cranial-brain trauma]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101 |
| Pharmacological interventions in primary care: hopes and illusions. | Frontiers of neurology and neuroscience 20090101 |
| Is it possible to treat vascular dementia? | Frontiers of neurology and neuroscience 20090101 |
| Dementia with Lewy bodies: clinical diagnosis and therapeutic approach. | Frontiers of neurology and neuroscience 20090101 |
| Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. | BMC neurology 20090101 |
| [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia]. | Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 20090101 |
| Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex. | Journal of Alzheimer's disease : JAD 20090101 |
| Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. | American journal of Alzheimer's disease and other dementias 20090101 |
| Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. | CNS drugs 20090101 |
| Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? | The open neurology journal 20090101 |
| Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20090101 |
| Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. | Alzheimer disease and associated disorders 20090101 |
| Dementia care initiative in primary practice: study protocol of a cluster randomized trial on dementia management in a general practice setting. | BMC health services research 20090101 |
| Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. | Drugs & aging 20090101 |
| Update on the use of memantine in Alzheimer's disease. | Neuropsychiatric disease and treatment 20090101 |
| DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. | Trials 20090101 |
| [Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer's disease]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101 |
| Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. | BMC neurology 20090101 |
| Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. | BMC neuroscience 20090101 |
| Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals. | BMC neurology 20090101 |
| Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients? | Dementia and geriatric cognitive disorders 20090101 |
| The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. | Indian journal of psychiatry 20090101 |
| Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect. | The Journal of neuropsychiatry and clinical neurosciences 20090101 |
| Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study. | Clinical drug investigation 20090101 |
| Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. | Alzheimer's research & therapy 20090101 |
| Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. | Dementia and geriatric cognitive disorders 20090101 |
| Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. | Open medicine : a peer-reviewed, independent, open-access journal 20090101 |
| Gender differences in the pharmacokinetics of rivastigmine in rats. | Arzneimittel-Forschung 20090101 |
| Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada. | BMC health services research 20090101 |
| Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India. | Indian journal of psychiatry 20090101 |
| Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels? | Neurologia i neurochirurgia polska 20090101 |
| Development and validation of a spectrofluorimetric method for the estimation of rivastigmine in formulations. | Indian journal of pharmaceutical sciences 20090101 |
| Treatment disparities in medication prescribing for Alzheimer's: disease among ethnic groups. | Journal of health care finance 20090101 |
| Mild cognitive impairment: The dilemma. | Indian journal of psychiatry 20090101 |
| Vascular cognitive impairment. | Indian journal of psychiatry 20090101 |
| Frontotemporal dementia: An updated overview. | Indian journal of psychiatry 20090101 |
| Memory clinics in context. | Indian journal of psychiatry 20090101 |
| Behavioral and psychological symptoms of dementia and their management. | Indian journal of psychiatry 20090101 |
| Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia. | Indian journal of psychiatry 20090101 |
| Screening the methanol extracts of some Iranian plants for acetylcholinesterase inhibitory activity. | Research in pharmaceutical sciences 20090101 |
| Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. | Expert opinion on drug delivery 20081201 |
| Acetylcholinesterase-inhibiting activity of pyrrole derivatives from a novel marine gliding bacterium, Rapidithrix thailandica. | Marine drugs 20081201 |
| Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. | Clinical interventions in aging 20081201 |
| Pharmacology and therapeutic potential of sigma(1) receptor ligands. | Current neuropharmacology 20081201 |
| Brain cholinergic impairment in liver failure. | Brain : a journal of neurology 20081101 |
| Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. | International journal of clinical practice 20081101 |
| Relative tolerability of Alzheimer's disease treatments. | Psychiatry (Edgmont (Pa. : Township)) 20081101 |
| Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. | Journal of neuroimmunology 20081015 |
| Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. | Journal of neural transmission (Vienna, Austria : 1996) 20081001 |
| Pharmacological treatment in moderate-to-severe Alzheimer's disease. | Expert opinion on pharmacotherapy 20081001 |
| Diagnosis and management of Parkinson's disease dementia. | International journal of clinical practice 20081001 |
| The efficacy of mirtazapine in agitated patients with Alzheimer's disease: A 12-week open-label pilot study. | Neuropsychiatric disease and treatment 20081001 |
| Errorless learning and spaced retrieval techniques to relearn instrumental activities of daily living in mild Alzheimer's disease: A case report study. | Neuropsychiatric disease and treatment 20081001 |
| Neuropharmacology. | Indian journal of pharmacology 20081001 |
| Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. | Chemico-biological interactions 20080925 |
| The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. | Chemico-biological interactions 20080925 |
| [Neuropsychiatric and cognitive symptoms in Parkinson disease]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080925 |
| Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. | The international journal of neuropsychopharmacology 20080901 |
| Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. | The Lancet. Neurology 20080901 |
| Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. | Current medical research and opinion 20080901 |
| [Alzheimer type dementia]. | Revue de l'infirmiere 20080901 |
| Effects of rivastigmine on memory and cognition in multiple sclerosis. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080901 |
| Drug utilization review of cholinesterase inhibitors in Quebec. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080901 |
| [A transdermal patch of rivastigmine (Exelon)]. | Revue medicale de Liege 20080901 |
| A study of rivastigmine liposomes for delivery into the brain through intranasal route. | Acta pharmaceutica (Zagreb, Croatia) 20080901 |
| Role of the central cholinergic system in the therapeutics of schizophrenia. | Current neuropharmacology 20080901 |
| Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. | Movement disorders : official journal of the Movement Disorder Society 20080815 |
| Rivastigmine in Parkinson's disease dementia. | Expert review of neurotherapeutics 20080801 |
| Delayed-onset hepatic encephalopathy induced by zolpidem: a case report. | Clinics (Sao Paulo, Brazil) 20080801 |
| Rivastigmine transdermal patch: role in the management of Alzheimer's disease. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080801 |
| The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. | Neuropsychiatric disease and treatment 20080801 |
| Current approaches to the treatment of Parkinson's disease. | Neuropsychiatric disease and treatment 20080801 |
| Present and prospective clinical therapeutic regimens for Alzheimer's disease. | Neuropsychiatric disease and treatment 20080801 |
| Psychiatric disorders and traumatic brain injury. | Neuropsychiatric disease and treatment 20080801 |
| Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. | Pharmacoepidemiology and drug safety 20080701 |
| Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20080701 |
| Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. | Journal of medicinal chemistry 20080612 |
| Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. | Psychopharmacology 20080601 |
| Complete atrioventricular block associated with rivastigmine therapy. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601 |
| Miniaturized membrane sensors for the determination of rivastigmine hydrogen tartrate. | Chemical & pharmaceutical bulletin 20080601 |
| Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease. | Endocrine, metabolic & immune disorders drug targets 20080601 |
| Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. | Journal of managed care pharmacy : JMCP 20080601 |
| Strategies for molecular imaging dementia and neurodegenerative diseases. | Neuropsychiatric disease and treatment 20080601 |
| Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). | Current neuropharmacology 20080601 |
| Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. | Journal of medicinal chemistry 20080522 |
| [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study]. | Revista de neurologia 20080501 |
| Dementia medications in palliative care #174. | Journal of palliative medicine 20080501 |
| [Treatment of Alzheimer's disease: status quo and future considerations]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080501 |
| Parkinson's disease in the elderly. | Medicine and health, Rhode Island 20080501 |
| Diagnosis and treatment of dementia with Lewy bodies. | JAAPA : official journal of the American Academy of Physician Assistants 20080501 |
| AAFP and ACP release guideline on dementia treatment. | American family physician 20080415 |
| Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. | Journal of medicinal chemistry 20080410 |
| In situ-forming oleogel implant for rivastigmine delivery. | Pharmaceutical research 20080401 |
| Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20080401 |
| The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. | Pharmacology, biochemistry, and behavior 20080401 |
| Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers. | Psychopharmacology 20080401 |
| Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. | Pharmacogenetics and genomics 20080401 |
| A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). | PLoS medicine 20080401 |
| [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)]. | Revista de neurologia 20080401 |
| Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease. | Neuropsychiatric disease and treatment 20080401 |
| A rivastigmine patch for dementia. | The Medical letter on drugs and therapeutics 20080324 |
| Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. | Brain research 20080320 |
| A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. | Macromolecular bioscience 20080310 |
| Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations. | Annals of internal medicine 20080304 |
| Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. | Annals of internal medicine 20080304 |
| Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. | Annals of internal medicine 20080304 |
| No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats. | European journal of nuclear medicine and molecular imaging 20080301 |
| [Antidementia drugs--response or non-response?]. | Der Internist 20080301 |
| How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. | European journal of neurology 20080301 |
| Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy. | Pharmacotherapy 20080301 |
| Pharmacodynamics of memantine: an update. | Current neuropharmacology 20080301 |
| Microcalorimetric study of the inhibition of butyrylcholinesterase by carbamates. | Analytical biochemistry 20080215 |
| Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. | International journal of geriatric psychiatry 20080201 |
| A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. | International journal of geriatric psychiatry 20080201 |
| Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. | International journal of geriatric psychiatry 20080201 |
| Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. | Sleep & breathing = Schlaf & Atmung 20080201 |
| Neurological signs in relation to type of cerebrovascular disease in vascular dementia. | Stroke 20080201 |
| Prolonged QT interval, syncope, and delirium with galantamine. | The Annals of pharmacotherapy 20080201 |
| Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. | Journal of clinical pharmacology 20080201 |
| Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. | Current Alzheimer research 20080201 |
| Pharmacologic management of Alzheimer disease. | The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20080201 |
| [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080131 |
| Cholinesterase inhibitors for delirium. | The Cochrane database of systematic reviews 20080123 |
| alpha,beta-Dehydrophenylalanine choline esters, a new class of reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase. | Chemico-biological interactions 20080110 |
| Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. | Clinical pharmacology and therapeutics 20080101 |
| The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. | Schizophrenia bulletin 20080101 |
| [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview]. | Der Nervenarzt 20080101 |
| Rivastigmine in Wernicke-Korsakoff's syndrome: five patients with rivastigmine showed no more improvement than five patients without rivastigmine. | Alcohol and alcoholism (Oxford, Oxfordshire) 20080101 |
| Identification of responders to rivastigmine: a prospective cohort study. | Dementia and geriatric cognitive disorders 20080101 |
| A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. | Current medical research and opinion 20080101 |
| Education and use of dementia drugs: a register-based study of over 600,000 older people. | Dementia and geriatric cognitive disorders 20080101 |
| Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. | Drug safety 20080101 |
| Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. | Journal of neuroinflammation 20080101 |
| Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia. | American journal of Alzheimer's disease and other dementias 20080101 |
| Pharmacogenomics in Alzheimer's disease. | Methods in molecular biology (Clifton, N.J.) 20080101 |
| [Treatment of Alzheimer's Disease cognitive symptoms]. | Vertex (Buenos Aires, Argentina) 20080101 |
| Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort. | BMC psychiatry 20080101 |
| Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. | Clinical drug investigation 20080101 |
| Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. | BMC health services research 20080101 |
| Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study. | Clinical drug investigation 20080101 |
| A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. | Behavioral and brain functions : BBF 20080101 |
| Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings. | Drugs & aging 20080101 |
| Fluorimetric determination of rivastigmine in rat plasma by a reverse phase--high performance liquid chromatographic method. Application to a pharmacokinetic study. | Arzneimittel-Forschung 20080101 |
| Pathophysiology and treatment of psychosis in Parkinson's disease: a review. | Drugs & aging 20080101 |
| Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. | Clinical interventions in aging 20080101 |
| A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. | Trials 20080101 |
| Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects. | Drugs & aging 20080101 |
| Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. | Primary care companion to the Journal of clinical psychiatry 20080101 |
| A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative. | BMC neurology 20080101 |
| [The treatment of Alzheimer's disease in patients with comorbid somatic pathology]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101 |
| The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. | Current medicinal chemistry 20080101 |
| Student pharmacists: don't forget the product labeling. | Journal of the American Pharmacists Association : JAPhA 20080101 |
| Neurological and psychiatric practitioners' views on Alzheimer's disease and treatment thereof. | Dementia and geriatric cognitive disorders 20080101 |
| Intranasal administration of acetylcholinesterase inhibitors. | BMC neuroscience 20080101 |
| A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy. | Arzneimittel-Forschung 20080101 |
| Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study. | Primary care companion to the Journal of clinical psychiatry 20080101 |
| Discontinuing Alzheimer's disease drug therapy: why, when, and how. | Director (Cincinnati, Ohio) 20080101 |
| Cognitive rehabilitation for reversible and progressive brain injury. | Indian journal of psychiatry 20080101 |
| Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. | Drug design, development and therapy 20080101 |
| Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. | Patient preference and adherence 20080101 |
| Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. | Journal of inflammation research 20080101 |
| Focusing effect of acetylcholine on neuroplasticity in the human motor cortex. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20071226 |
| [Pharmacological treatment options in frontotemporal dementia]. | Fortschritte der Neurologie-Psychiatrie 20071201 |
| A new lupene triterpenetriol and anticholinesterase activity of Salvia sclareoides. | Fitoterapia 20071201 |
| Rivastigmine exposure provided by a transdermal patch versus capsules. | Current medical research and opinion 20071201 |
| Rivastigmine-induced dystonia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071201 |
| An update on the pharmacology of galantamine. | Expert opinion on investigational drugs 20071201 |
| Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study. | Psychiatry and clinical neurosciences 20071201 |
| Management of the behavioral and psychological symptoms of dementia. | Clinical interventions in aging 20071201 |
| The challenge of supporting care for dementia in primary care. | Clinical interventions in aging 20071201 |
| Rivastigmine in Alzheimer's disease: Cognitive function and quality of life. | Therapeutics and clinical risk management 20071201 |
| A review on primary progressive aphasia. | Neuropsychiatric disease and treatment 20071201 |
| Rivastigmine for the treatment of dementia associated with Parkinson's disease. | Neuropsychiatric disease and treatment 20071201 |
| Rivastigmine in Chinese patients with subcortical vascular dementia. | Neuropsychiatric disease and treatment 20071201 |
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | Current neuropharmacology 20071201 |
| Current therapeutic options for Alzheimer's disease. | Current genomics 20071201 |
| [Rivastigmine against dementia in Parkinson disease?]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20071115 |
| A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. | Current medical research and opinion 20071101 |
| A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. | Expert review of neurotherapeutics 20071101 |
| Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. | PLoS medicine 20071101 |
| N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. | European journal of pharmacology 20071031 |
| Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. | Journal of medicinal chemistry 20071004 |
| Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. | Journal of neurology, neurosurgery, and psychiatry 20071001 |
| Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates. | International journal of geriatric psychiatry 20071001 |
| [Lewy body dementia and Parkinson disease dementia]. | Presse medicale (Paris, France : 1983) 20071001 |
| Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. | Journal of the American Geriatrics Society 20071001 |
| Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study. | Current medical research and opinion 20071001 |
| Evaluation of centrally acting cholinesterase inhibitor exposures in adults. | The Annals of pharmacotherapy 20071001 |
| Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. | Journal of clinical psychopharmacology 20071001 |
| Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease. | Prescrire international 20071001 |
| Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20071001 |
| Pharmacotherapy of Alzheimer disease. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20071001 |
| [Cardiovascular effects of cholinesterase inhibitors in Alzheimer's disease]. | Revue neurologique 20071001 |
| Diagnosis and management of vascular cognitive impairment. | Current atherosclerosis reports 20071001 |
| Progress update: Pharmacological treatment of Alzheimer's disease. | Neuropsychiatric disease and treatment 20071001 |
| Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. | Neuropsychiatric disease and treatment 20071001 |
| [Are anti-dementia drugs worthwhile?]. | MMW Fortschritte der Medizin 20070913 |
| Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. | International journal of geriatric psychiatry 20070901 |
| Motor-skill learning in Alzheimer's disease: a review with an eye to the clinical practice. | Neuropsychology review 20070901 |
| Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. | The Lancet. Neurology 20070901 |
| Anti-dementia drugs and hippocampal-dependent memory in rodents. | Behavioural pharmacology 20070901 |
| NICE judgement leaves behind a nasty taste. | Nursing older people 20070901 |
| Vascular dementia: pharmacological treatment approaches and perspectives. | Clinical interventions in aging 20070901 |
| Pharmacokinetic rationale for the rivastigmine patch. | Neurology 20070724 |
| IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. | Neurology 20070724 |
| Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. | Neurology 20070724 |
| Rationale for transdermal drug administration in Alzheimer disease. | Neurology 20070724 |
| Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study. | Neurology 20070703 |
| Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. | Current Alzheimer research 20070701 |
| Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. | Journal of Alzheimer's disease : JAD 20070701 |
| Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. | Methods and findings in experimental and clinical pharmacology 20070701 |
| A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601 |
| The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. | Molecular pharmacology 20070601 |
| Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. | International psychogeriatrics 20070601 |
| Memory enhancing drugs and Alzheimer's disease: enhancing the self or preventing the loss of it? | Medicine, health care, and philosophy 20070601 |
| EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. | International journal of clinical practice 20070601 |
| MCI treatment trials: failure or not? | The Lancet. Neurology 20070601 |
| Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. | The Lancet. Neurology 20070601 |
| [Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies]. | Deutsche medizinische Wochenschrift (1946) 20070601 |
| [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)]. | Revista de neurologia 20070601 |
| Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. | Drugs of today (Barcelona, Spain : 1998) 20070601 |
| Atypical antipsychotics for the treatment of dementia-related behaviors: an update. | Medicine and health, Rhode Island 20070601 |
| Treating senile dementia with traditional Chinese medicine. | Clinical interventions in aging 20070601 |
| The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. | Neuropsychiatric disease and treatment 20070601 |
| Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. | Neuropsychiatric disease and treatment 20070601 |
| [Acetylcholinesterase inhibitors for dementia--an update]. | MMW Fortschritte der Medizin 20070521 |
| Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. | Neurology 20070515 |
| Effects of rivastigmine on cognitive function in patients with traumatic brain injury. | Neurology 20070515 |
| Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. | Pharmacoepidemiology and drug safety 20070501 |
| Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. | Psychopharmacology 20070501 |
| Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. | Nature clinical practice. Neurology 20070501 |
| A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. | International journal of geriatric psychiatry 20070501 |
| Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. | Life sciences 20070501 |
| Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. | International journal of geriatric psychiatry 20070501 |
| Effective pharmacologic management of Alzheimer's disease. | The American journal of medicine 20070501 |
| [Hallucinations associated to treatment with rivastigmine in two patients with diffuse Lewy body disease]. | Revista de neurologia 20070501 |
| Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease. | Journal of the American Geriatrics Society 20070501 |
| Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. | International journal of geriatric psychiatry 20070401 |
| Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. | International journal of geriatric psychiatry 20070401 |
| Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. | Journal of clinical pharmacology 20070401 |
| Rivastigmine and Parkinson dementia complex. | Expert opinion on pharmacotherapy 20070401 |
| Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you! | Prescrire international 20070401 |
| Rivastigmine in the treatment of patients with Alzheimer's disease. | Neuropsychiatric disease and treatment 20070401 |
| Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. | Neuropsychiatric disease and treatment 20070401 |
| Modulation of human motor cortex excitability by the cholinesterase inhibitor rivastigmine. | Neuroscience letters 20070319 |
| Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor. | Journal of chromatography. A 20070309 |
| The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease. | Journal of the American Medical Directors Association 20070301 |
| Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. | Current medical research and opinion 20070301 |
| Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20070301 |
| Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20070301 |
| Rivastigmine in the treatment of Alzheimer's disease: an update. | Clinical interventions in aging 20070301 |
| [Synthesis of S-(+)-rivastigmine hydrogentartrate]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070201 |
| Impaired cognition and attention in adults: pharmacological management strategies. | Neuropsychiatric disease and treatment 20070201 |
| Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. | Journal of neurology, neurosurgery, and psychiatry 20070101 |
| Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. | Archives of gerontology and geriatrics 20070101 |
| Treatment of vascular dementia and vascular cognitive impairment. | The neurologist 20070101 |
| Strategies to improve tolerability of rivastigmine: a case series. | Current medical research and opinion 20070101 |
| Two years' follow-up of rivastigmine treatment in Huntington disease. | Clinical neuropharmacology 20070101 |
| Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis. | Drugs & aging 20070101 |
| Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl). | Archives of gerontology and geriatrics 20070101 |
| Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. | Neurologia i neurochirurgia polska 20070101 |
| Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. | Dementia and geriatric cognitive disorders 20070101 |
| Treatment of delusions in dementia with Lewy bodies - response to pharmacotherapy. | Dementia and geriatric cognitive disorders 20070101 |
| Rivastigmine in Parkinson's disease dementia: profile report. | Drugs & aging 20070101 |
| Nonenzymatic functions of acetylcholinesterase splice variants in the developmental neurotoxicity of organophosphates: chlorpyrifos, chlorpyrifos oxon, and diazinon. | Environmental health perspectives 20070101 |
| Advancing translational research with the Semantic Web. | BMC bioinformatics 20070101 |
| Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. | American journal of Alzheimer's disease and other dementias 20070101 |
| Inhibition of cholinesterase by dialkylcarbamates. | Zeitschrift fur Naturforschung. C, Journal of biosciences 20070101 |
| Frontotemporal dementias: a review. | Annals of general psychiatry 20070101 |
| The Hawthorne Effect: a randomised, controlled trial. | BMC medical research methodology 20070101 |
| [Transdermal drugs in neurology]. | Neurologia (Barcelona, Spain) 20070101 |
| Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. | Neurologia i neurochirurgia polska 20070101 |
| Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances. | Functional neurology 20070101 |
| Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. | BMC neuroscience 20070101 |
| Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. | Pharmacological reports : PR 20070101 |
| Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease. | PloS one 20070101 |
| Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease. | Advances in therapy 20070101 |
| Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors. | Acta bio-medica : Atenei Parmensis 20070101 |
| Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease. | Acta neurobiologiae experimentalis 20070101 |
| The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. | BMC neurology 20070101 |
| Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. | Clinical neuropharmacology 20070101 |
| Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. | PharmacoEconomics 20070101 |
| Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type. | CNS drugs 20070101 |
| Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? | Drugs & aging 20070101 |
| Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). | Drug safety 20070101 |
| Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. | Current medicinal chemistry 20070101 |
| Cerebral acetylcholinesterase imaging: development of the radioprobes. | Current topics in medicinal chemistry 20070101 |
| Validation of a method for identifying nursing home admissions using administrative claims. | BMC health services research 20070101 |
| Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice. | Bioinformation 20070101 |
| Neuropsychological rehabilitation in mild and moderate Alzheimer's disease patients. | Behavioural neurology 20070101 |
| The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. | British journal of pharmacology 20061201 |
| [Diagnosis and clinical therapy for Parkinson's disease]. | Der Nervenarzt 20061201 |
| Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease. | Evidence-based complementary and alternative medicine : eCAM 20061201 |
| Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. | Neurotoxicity research 20061201 |
| Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. | Journal of child and adolescent psychopharmacology 20061201 |
| Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. | Neuropsychiatric disease and treatment 20061201 |
| 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. | Bioorganic & medicinal chemistry letters 20061115 |
| Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. | Journal of neural transmission (Vienna, Austria : 1996) 20061101 |
| Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20061101 |
| Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. | Pharmacogenetics and genomics 20061101 |
| Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. | Journal of psychopharmacology (Oxford, England) 20061101 |
| A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. | Current medical research and opinion 20061101 |
| Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. | Journal of psychiatry & neuroscience : JPN 20061101 |
| [Medical treatment of Alzheimer's disease]. | Ugeskrift for laeger 20061002 |
| A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061001 |
| Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. | Movement disorders : official journal of the Movement Disorder Society 20061001 |
| [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine]. | Revista de neurologia 20061001 |
| Use of antidementia agents in vascular dementia: beyond Alzheimer disease. | Mayo Clinic proceedings 20061001 |
| Unsubstantiated superiority claims for rivastigmine tartrate. | The Journal of the American Osteopathic Association 20061001 |
| Effects of rivastigmine on cognitive function in patients with traumatic brain injury. | Neurology 20060912 |
| Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. | Acta pharmacologica Sinica 20060901 |
| Do caregivers' experiences correspond with the concerns raised in the literature? Ethical issues relating to anti-dementia drugs. | International journal of geriatric psychiatry 20060901 |
| Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. | Journal of neurology 20060901 |
| Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. | The American journal of geriatric pharmacotherapy 20060901 |
| Vascular dementia: prevention and treatment. | Clinical interventions in aging 20060901 |
| [Advances in Alzheimer's disease treatment]. | La Revue de medecine interne 20060801 |
| [Cholinesterase inhibitor therapy in long term care settings]. | La Revue de medecine interne 20060801 |
| Alzheimer's disease. | Lancet (London, England) 20060729 |
| Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. | Progress in neuro-psychopharmacology & biological psychiatry 20060701 |
| Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. | Schizophrenia research 20060701 |
| Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20060701 |
| [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease]. | Tijdschrift voor gerontologie en geriatrie 20060701 |
| Dementia with lewy bodies: therapeutic opportunities and pitfalls. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20060701 |
| Are there protective treatments for cognitive decline in MS? | Journal of the neurological sciences 20060615 |
| Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. | The Journal of pharmacology and experimental therapeutics 20060601 |
| Alzheimer's disease: beware of interactions with cholinesterase inhibitors. | Prescrire international 20060601 |
| Antipsychotic drug use among nursing home residents taking rivastigmine. | Journal of the American Medical Directors Association 20060601 |
| Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. | International journal of clinical practice 20060601 |
| Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. | International journal of clinical practice 20060601 |
| Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. | The American journal of geriatric pharmacotherapy 20060601 |
| Treatment of Alzheimer's disease across the spectrum of severity. | Clinical interventions in aging 20060601 |
| Economic considerations in the management of Alzheimer's disease. | Clinical interventions in aging 20060601 |
| Memantine combined with an acetyl cholinesterase inhibitor - hope for the future? | Neuropsychiatric disease and treatment 20060601 |
| [Anti-dementia drugs for dementia syndromes--just unkept promises?]. | MMW Fortschritte der Medizin 20060515 |
| Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. | The Journal of pharmacology and experimental therapeutics 20060501 |
| Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen. | International journal of clinical practice 20060501 |
| Differential acetylcholinesterase activity in rat cerebrum, cerebellum and hypothalamus. | Indian journal of experimental biology 20060501 |
| Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. | Neurology 20060411 |
| Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. | Journal of medicinal chemistry 20060406 |
| Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. | Movement disorders : official journal of the Movement Disorder Society 20060401 |
| Clinical trials in mild cognitive impairment: lessons for the future. | Journal of neurology, neurosurgery, and psychiatry 20060401 |
| Cholinesterase inhibitors: drugs looking for a disease? | PLoS medicine 20060401 |
| Pharmacological manipulation of the vasoconstrictive effects of amyloid-beta peptides by donepezil and rivastigmine. | Current Alzheimer research 20060401 |
| [Anticholinesterases in the treatment of Alzheimer's disease]. | Revista de neurologia 20060401 |
| Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? | Alzheimer's & dementia : the journal of the Alzheimer's Association 20060401 |
| Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. | Brain research bulletin 20060331 |
| Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings. | Journal of geriatric psychiatry and neurology 20060301 |
| Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementia. | The Nursing clinics of North America 20060301 |
| Appeals system and its outcomes in national health insurance in Taiwan. | The Annals of pharmacotherapy 20060301 |
| National patterns of dementia treatment among elderly ambulatory patients. | Journal of the National Medical Association 20060301 |
| Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. | Current medical research and opinion 20060301 |
| Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. | Brain research 20060216 |
| Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20060201 |
| Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. | Mechanisms of ageing and development 20060201 |
| Quetiapine and rivastigmine for agitation in Alzheimer's disease. | Current psychiatry reports 20060201 |
| Cholinesterase inhibitors for Parkinson's disease dementia. | The Cochrane database of systematic reviews 20060125 |
| Cholinesterase inhibitors for Alzheimer's disease. | The Cochrane database of systematic reviews 20060125 |
| Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. | NeuroImage 20060115 |
| A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. | International journal of geriatric psychiatry 20060101 |
| Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. | International journal of geriatric psychiatry 20060101 |
| Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. | Acta pharmacologica Sinica 20060101 |
| Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. | Emergency medicine journal : EMJ 20060101 |
| Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. | Dementia and geriatric cognitive disorders 20060101 |
| Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. | Current medical research and opinion 20060101 |
| Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. | International journal of clinical practice 20060101 |
| The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. | Health technology assessment (Winchester, England) 20060101 |
| Antipsychotic drug use among nursing home residents taking rivastigmine. | Journal of the American Medical Directors Association 20060101 |
| Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. | PharmacoEconomics 20060101 |
| Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease. | Pharmacopsychiatry 20060101 |
| QEEG monitoring of Alzheimer's disease treatment: a preliminary report of three case studies. | Clinical EEG and neuroscience 20060101 |
| A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. | Drugs & aging 20060101 |
| Current and emerging pharmacological treatment options for dementia. | Behavioural neurology 20060101 |
| Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. | Alzheimer disease and associated disorders 20060101 |
| [Are the prescriptions of anticholinesterasic drugs adapted to the associated diseases and/or drugs in the Alzheimer's dementia?]. | Therapie 20060101 |
| Transdermal treatment options for neurological disorders: impact on the elderly. | Drugs & aging 20060101 |
| Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. | Drugs & aging 20060101 |
| Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease. | Annals of general psychiatry 20060101 |
| A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. | Primary care companion to the Journal of clinical psychiatry 20060101 |
| Rivastigmine: in Parkinson's disease dementia. | CNS drugs 20060101 |
| [Pharmacotherapy for Alzheimer's disease]. | Tijdschrift voor psychiatrie 20060101 |
| Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. | The Journal of international medical research 20060101 |
| Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. | CNS drugs 20060101 |
| A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20060101 |
| Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. | Journal of biomedicine & biotechnology 20060101 |
| Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. | Journal of biomedicine & biotechnology 20060101 |
| Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes. | Rapid communications in mass spectrometry : RCM 20060101 |
| Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients. | Drug safety 20060101 |
| Realistic expectations for treatment success in Alzheimer's disease. | The journal of nutrition, health & aging 20060101 |
| Management of Parkinson's disease dementia : practical considerations. | Drugs & aging 20060101 |
| Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? | Lipids in health and disease 20060101 |
| [Pharmacological approaches to the therapy of Alzheimer's disease]. | Vestnik Rossiiskoi akademii meditsinskikh nauk 20060101 |
| Alzheimer disease and its management: a review. | American journal of therapeutics 20060101 |
| Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease. | Alzheimer disease and associated disorders 20060101 |
| Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. | BMC neuroscience 20060101 |
| The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. | Current medicinal chemistry 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study. | Primary care companion to the Journal of clinical psychiatry 20060101 |
| First treatment for dementia of Parkinson's disease. | FDA consumer 20060101 |
| Neurogenesis and Alzheimer's disease. | Drug target insights 20060101 |
| Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. | Core evidence 20060101 |
| Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents. | Chemico-biological interactions 20051215 |
| Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. | The Journal of pharmacology and experimental therapeutics 20051201 |
| Discontinuation of rivastigmine in routine clinical practice. | International journal of geriatric psychiatry 20051201 |
| Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study. | Clinical rehabilitation 20051201 |
| Dementia. | Clinical evidence 20051201 |
| Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment. | Neuropsychiatric disease and treatment 20051201 |
| Benefits of rivastigmine on attention in dementia associated with Parkinson disease. | Neurology 20051122 |
| Power surge: renewed interest in nuclear energy. | Environmental health perspectives 20051101 |
| Behavioral and neuropsychiatric outcomes in Alzheimer's disease. | CNS spectrums 20051101 |
| Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. | Current medical research and opinion 20051101 |
| Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. | Brain research 20051026 |
| The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. | British journal of pharmacology 20051001 |
| Pharmacogenomics and therapeutic prospects in Alzheimer's disease. | Expert opinion on pharmacotherapy 20051001 |
| Treatment approaches to symptoms associated with frontotemporal degeneration. | Current psychiatry reports 20051001 |
| Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. | Current medical research and opinion 20051001 |
| Reimbursement decisions in health policy--extending our understanding of the elements of decision-making. | Health policy (Amsterdam, Netherlands) 20050908 |
| [Nightmares in patients with Alzheimer's disease caused by donepezil. Therapeutic effect depends on the time of intake]. | Der Nervenarzt 20050901 |
| Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. | Bioorganic & medicinal chemistry letters 20050901 |
| Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. | Psychopharmacology 20050901 |
| Rivastigmine for Alzheimer's disease. | Expert review of neurotherapeutics 20050901 |
| UK government guidance on Alzheimer's drugs postponed. | Drug discovery today 20050901 |
| Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study. | The Ceylon medical journal 20050901 |
| Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. | The American journal of geriatric pharmacotherapy 20050901 |
| Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. | BMJ (Clinical research ed.) 20050806 |
| Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells. | British journal of pharmacology 20050801 |
| One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. | Human psychopharmacology 20050801 |
| Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. | Journal of clinical psychopharmacology 20050801 |
| Neurophysiological predictors of long term response to AChE inhibitors in AD patients. | Journal of neurology, neurosurgery, and psychiatry 20050801 |
| Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. | Current medical research and opinion 20050801 |
| Pesticide-like poisoning from a prescription drug. | The New England journal of medicine 20050721 |
| Enantioselective separation of rivastigmine by capillary electrophoresis with cyclodextrines. | Journal of chromatography. A 20050715 |
| A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. | European journal of clinical pharmacology 20050701 |
| Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. | International journal of clinical practice 20050701 |
| Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. | Journal of neurology, neurosurgery, and psychiatry 20050701 |
| Rivastigmine for dementia associated with Parkinson's disease. | Current neurology and neuroscience reports 20050701 |
| [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands]. | Tijdschrift voor gerontologie en geriatrie 20050701 |
| Treatment persistency with rivastigmine and donepezil in a large state medicaid program. | Journal of the American Geriatrics Society 20050701 |
| A validated chiral liquid chromatographic method for the enantiomeric separation of Rivastigmine hydrogen tartarate, a cholinesterase inhibitor. | Journal of pharmaceutical and biomedical analysis 20050615 |
| Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. | Psychopharmacology 20050601 |
| A study paradigm allowing comparison of multiple high-resolution rCBV-maps for the examination of drug effects. | NMR in biomedicine 20050601 |
| Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy. | International journal of geriatric psychiatry 20050601 |
| Recent important trials of pharmacotherapy in Parkinson's disease. | Expert opinion on pharmacotherapy 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| [Changing the anticholinesterase in Alzheimer's disease]. | Revista de neurologia 20050601 |
| Rivastigmine modestly improves dementia associated with Parkinson's disease, but has important adverse effects. | Evidence-based mental health 20050501 |
| Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. | Annals of neurology 20050501 |
| Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome. | International journal of geriatric psychiatry 20050501 |
| Rivastigmine for subcortical vascular dementia. | Expert review of neurotherapeutics 20050501 |
| Psychiatric aspects of Parkinson's disease. | Current opinion in psychiatry 20050501 |
| Rivastigmine for vascular cognitive impairment. | The Cochrane database of systematic reviews 20050418 |
| Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. | BMJ (Clinical research ed.) 20050416 |
| Drugs for Alzheimer's disease and related dementias. | BMJ (Clinical research ed.) 20050416 |
| Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. | Journal of managed care pharmacy : JMCP 20050401 |
| Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. | International journal of clinical practice 20050401 |
| Rivastigmine for dementia associated with Parkinson's disease. | The New England journal of medicine 20050331 |
| NICE proposes to withdraw Alzheimer's drugs from NHS. | BMJ (Clinical research ed.) 20050305 |
| Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease. | The Lancet. Neurology 20050301 |
| Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia. | Journal of psychopharmacology (Oxford, England) 20050301 |
| The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. | Experimental gerontology 20050301 |
| Cholinesterase inhibitors in the treatment of dementia. | The Journal of the American Osteopathic Association 20050301 |
| Effects of rivastigmine in a case of residual schizophrenia. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20050301 |
| Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. | Journal of the American Academy of Nurse Practitioners 20050301 |
| Mild cognitive impairment in Parkinson's disease: the challenge and the promise. | Neuropsychiatric disease and treatment 20050301 |
| Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. | Journal of medicinal chemistry 20050224 |
| Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. | European journal of pharmacology 20050221 |
| Seizures associated with memantine use. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050215 |
| A stability indicating LC method for rivastigmine hydrogen tartrate. | Journal of pharmaceutical and biomedical analysis 20050207 |
| [Acetylcholinesterase inhibitor treatment for Alzheimer's disease: the experience in Picardy]. | Revue neurologique 20050201 |
| Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression. | Dementia and geriatric cognitive disorders 20050101 |
| A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. | Dementia and geriatric cognitive disorders 20050101 |
| Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. | Progress in neuro-psychopharmacology & biological psychiatry 20050101 |
| Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. | Dementia and geriatric cognitive disorders 20050101 |
| Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. | BMC geriatrics 20050101 |
| Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. | Dementia and geriatric cognitive disorders 20050101 |
| Integrated treatment approach improves cognitive function in demented and clinically depressed patients. | American journal of Alzheimer's disease and other dementias 20050101 |
| Dementia treatment update. | Geriatric nursing (New York, N.Y.) 20050101 |
| Heterocyclic inhibitors of AChE acylation and peripheral sites. | Farmaco (Societa chimica italiana : 1989) 20050101 |
| [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20050101 |
| Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. | Current medical research and opinion 20050101 |
| [Pharmacology of Alzheimer's disease: where do we go from here?]. | Therapie 20050101 |
| The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease. | Journal of the American Medical Directors Association 20050101 |
| The impact of acetylcholinergic medications on Alzheimer's disease-related behavioral disorders in nursing home patients: what is the real impact? | Journal of the American Medical Directors Association 20050101 |
| Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. | Drugs & aging 20050101 |
| Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. | Dementia and geriatric cognitive disorders 20050101 |
| Drug therapy of dementia in elderly patients. A review. | Nordic journal of psychiatry 20050101 |
| The potential value of negative studies. | Journal of the American Medical Directors Association 20050101 |
| Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. | PharmacoEconomics 20050101 |
| Short-term treatment with rivastigmine and plasma levels of Abeta peptides in Alzheimer's disease. | Folia neuropathologica 20050101 |
| Poisoning with rivastigmine. | Clinical toxicology (Philadelphia, Pa.) 20050101 |
| [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia]. | Revista espanola de salud publica 20050101 |
| Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. | Drugs & aging 20050101 |
| Melaena following Use of the Cholinesterase Inhibitor Rivastigmine. | Clinical drug investigation 20050101 |
| Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease : results of a 52-week open-label study. | Clinical drug investigation 20050101 |
| Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. | Neurology 20041228 |
| Rivastigmine for dementia associated with Parkinson's disease. | The New England journal of medicine 20041209 |
| Parkinson's disease dementia--a first step? | The New England journal of medicine 20041209 |
| [Dementia-current knowledge and significance for ENT specialists]. | HNO 20041201 |
| Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. | Movement disorders : official journal of the Movement Disorder Society 20041201 |
| The neuropsychiatry of Parkinson's disease and related disorders. | The Psychiatric clinics of North America 20041201 |
| Dementia. | Clinical evidence 20041201 |
| Pharmacotherapy of mild cognitive impairment. | Dialogues in clinical neuroscience 20041201 |
| Mild cognitive impairment: historical development and summary of research. | Dialogues in clinical neuroscience 20041201 |
| [Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease]. | Nederlands tijdschrift voor geneeskunde 20041127 |
| Impact of APOE in mild cognitive impairment. | Neurology 20041123 |
| Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. | Journal of medicinal chemistry 20041118 |
| Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors. | Journal of the neurological sciences 20041115 |
| [Are there innovations in the treatment of Parkinson's disease?]. | Praxis 20041103 |
| Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. | The Annals of pharmacotherapy 20041101 |
| Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. | International clinical psychopharmacology 20041101 |
| Switching from donepezil or rivastigmine to galantamine in clinical practice. | Journal of the American Geriatrics Society 20041101 |
| Neuropsychological rehabilitation of memory deficits and activities of daily living in patients with Alzheimer's disease: a pilot study. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20041101 |
| An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. | Current medical research and opinion 20041101 |
| Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. | Progress in neuro-psychopharmacology & biological psychiatry 20041101 |
| Fluctuations in cognition and alertness in Parkinson's disease and dementia. | Neurology 20041026 |
| Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens. | European journal of pharmacology 20041025 |
| [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]. | Nederlands tijdschrift voor geneeskunde 20041023 |
| Acetylcholinesterase inhibitors: novel activities of old molecules. | Pharmacological research 20041001 |
| Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. | CNS spectrums 20041001 |
| Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. | Current medical research and opinion 20041001 |
| Cognitive dysfunction and dementia in Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20041001 |
| Evidence-based pharmacotherapy of Alzheimer's disease. | The international journal of neuropsychopharmacology 20040901 |
| Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. | Neuropharmacology 20040901 |
| Adding rivastigmine to antipsychotics in the treatment of a chronic delirium. | Age and ageing 20040901 |
| The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. | Expert opinion on drug safety 20040901 |
| Memantine: pharmacological properties and clinical uses. | Neurology India 20040901 |
| Dementia in idiopathic Parkinson's syndrome. | Journal of neurology 20040901 |
| Behavioral disturbances in Parkinson's disease. | Dialogues in clinical neuroscience 20040901 |
| Dementia with Lewy bodies. | Dialogues in clinical neuroscience 20040901 |
| Drug treatment of Parkinson's disease. | Dialogues in clinical neuroscience 20040901 |
| Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. | Experimental neurology 20040801 |
| [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine]. | Revista de neurologia 20040801 |
| Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20040801 |
| [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine]. | Nederlands tijdschrift voor geneeskunde 20040724 |
| Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040705 |
| A case study in the treatment of dementia with Lewy bodies. | Acta psychiatrica Scandinavica 20040701 |
| What is the rationale for new treatment strategies in Alzheimer's disease? | CNS spectrums 20040701 |
| Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. | CNS spectrums 20040701 |
| Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage. | International journal of geriatric psychiatry 20040701 |
| Psychiatric aspects of Parkinson's disease--an update. | Journal of neurology 20040701 |
| Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. | Neurological research 20040701 |
| Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. | Clinical therapeutics 20040701 |
| Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. | Journal of clinical pharmacology 20040601 |
| Rivastigmine in vascular dementia. | Expert opinion on pharmacotherapy 20040601 |
| Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. | International journal of geriatric psychiatry 20040601 |
| Dementia. | Clinical evidence 20040601 |
| [Current antidementive therapy]. | MMW Fortschritte der Medizin 20040524 |
| Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. | Neuroscience letters 20040506 |
| Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain. | Clinical and experimental hypertension (New York, N.Y. : 1993) 20040501 |
| Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. | Clinical therapeutics 20040501 |
| [Current therapies in dementia]. | Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20040501 |
| Behavioral symptoms in mild cognitive impairment. | Neurology 20040413 |
| Emerging therapies for vascular dementia and vascular cognitive impairment. | Stroke 20040401 |
| Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. | Journal of neurology, neurosurgery, and psychiatry 20040401 |
| Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. | European journal of neurology 20040401 |
| A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. | Biomedical chromatography : BMC 20040401 |
| Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. | International journal of clinical practice 20040401 |
| Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. | Journal of neurochemistry 20040301 |
| Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. | International journal of geriatric psychiatry 20040301 |
| Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. | Journal of child neurology 20040301 |
| Treatment goals: response and nonresponse. | Dialogues in clinical neuroscience 20040301 |
| Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging. | Stroke 20040201 |
| Prediction of treatment response to rivastigmine in Alzheimer's dementia. | Journal of neurology, neurosurgery, and psychiatry 20040201 |
| Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. | Dementia and geriatric cognitive disorders 20040101 |
| Pharmacologic treatment expectations in the management of dementia with Lewy bodies. | Dementia and geriatric cognitive disorders 20040101 |
| 'Closing-in' phenomenon in Alzheimer's disease and subcortical vascular dementia. | BMC neurology 20040101 |
| Acetylcholinesterase inhibition in Alzheimer's Disease. | Current pharmaceutical design 20040101 |
| Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. | Drugs & aging 20040101 |
| Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. | Dementia and geriatric cognitive disorders 20040101 |
| Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101 |
| Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. | Drugs & aging 20040101 |
| Acetylcholinesterase imaging: its use in therapy evaluation and drug design. | Current pharmaceutical design 20040101 |
| [The virtual synapse what is its contribution to understanding cholinergic neural transmission?]. | Therapie 20040101 |
| Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study. | Archives of gerontology and geriatrics. Supplement 20040101 |
| Behavioral disturbances in Alzheimer's disease: a non-pharmacological therapeutic approach. | Archives of gerontology and geriatrics. Supplement 20040101 |
| What are the treatment options for patients with severe Alzheimer's disease? | CNS drugs 20040101 |
| The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available? | Journal of the American Medical Directors Association 20040101 |
| Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration. | Dementia and geriatric cognitive disorders 20040101 |
| Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101 |
| Rivastigmine in Alzheimer disease: efficacy over two years. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20040101 |
| Noncognitive symptoms and long-term treatment expectations for Alzheimer disease. | Alzheimer disease and associated disorders 20040101 |
| The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias. | Alzheimer disease and associated disorders 20040101 |
| Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease? | Neuroepidemiology 20040101 |
| Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. | The pharmacogenomics journal 20040101 |
| Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. | Clinical neuropharmacology 20040101 |
| Long-term cholinesterase inhibitor treatment of Alzheimer's disease. | CNS drugs 20040101 |
| Disease stage in Alzheimer disease and treatment effects of rivastigmine. | Alzheimer disease and associated disorders 20040101 |
| An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. | Current pharmaceutical design 20040101 |
| Recent approaches to novel anti-Alzheimer therapy. | Current pharmaceutical design 20040101 |
| New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. | Current pharmaceutical design 20040101 |
| Rivastigmine in frontotemporal dementia: an open-label study. | Drugs & aging 20040101 |
| Impact of rivastigmine use on the risk of nursing home placement in a US sample. | CNS drugs 20040101 |
| The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. | The Journal of neuropsychiatry and clinical neurosciences 20040101 |
| Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients. | American journal of Alzheimer's disease and other dementias 20040101 |
| [The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years]. | Neurologia i neurochirurgia polska 20040101 |
| The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. | Journal of the neurological sciences 20031215 |
| Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. | Brain : a journal of neurology 20031201 |
| A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease. | Journal of Alzheimer's disease : JAD 20031201 |
| Nightmares without atonia as an early symptom of diffuse Lewy bodies disease. | Arquivos de neuro-psiquiatria 20031201 |
| Italian drug policy: ethical aims of essential assistance levels. | Health care analysis : HCA : journal of health philosophy and policy 20031201 |
| Decisions on inclusion in the Swedish basic health care package--roles of cost-effectiveness and need. | Health care analysis : HCA : journal of health philosophy and policy 20031201 |
| Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. | International psychogeriatrics 20031201 |
| Severe worsening of parkinsonism in Lewy body dementia due to donepezil. | Neurology 20031125 |
| Rivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons. | British journal of pharmacology 20031101 |
| The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. | Molecular pharmacology 20031101 |
| Stereochemistry in clinical medicine: a neurological perspective. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20031101 |
| Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. | Acta neurologica Scandinavica 20031101 |
| Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. | Pharmacopsychiatry 20031101 |
| Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. | International journal of clinical practice 20031101 |
| [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study]. | Presse medicale (Paris, France : 1983) 20031025 |
| Editorial comment--How to treat vascular dementia? | Stroke 20031001 |
| Treatment of dementia with neurotransmission modulation. | Expert opinion on investigational drugs 20031001 |
| Pharmacologic treatment of Alzheimer's disease: an update. | American family physician 20031001 |
| Dementia with Lewy bodies. Review of diagnosis and pharmacologic management. | Canadian family physician Medecin de famille canadien 20031001 |
| Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030916 |
| Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman. | Journal of the American Geriatrics Society 20030901 |
| Treatment of Alzheimer's disease: current status and new perspectives. | The Lancet. Neurology 20030901 |
| Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? | International journal of geriatric psychiatry 20030901 |
| [Subcortical vascular encephalopathy]. | Therapeutische Umschau. Revue therapeutique 20030901 |
| Update on rivastigmine. | The neurologist 20030901 |
| Influence of cholinergic circuitries in generation of high-frequency somatosensory evoked potentials. | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20030801 |
| Alzheimer's disease: the pharmacological pathway. | Fundamental & clinical pharmacology 20030801 |
| Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. | European journal of pharmacology 20030704 |
| [Acetylcholinesterase inhibitors]. | Revue medicale de la Suisse romande 20030701 |
| [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. | Nederlands tijdschrift voor geneeskunde 20030621 |
| Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease. | Neuroscience letters 20030612 |
| Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. | The Journal of pharmacology and experimental therapeutics 20030601 |
| The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. | Journal of neural transmission (Vienna, Austria : 1996) 20030601 |
| Rivastigmine and QT interval prolongation. | The British journal of psychiatry : the journal of mental science 20030601 |
| Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease. | International journal of geriatric psychiatry 20030601 |
| Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. | Archives of neurology 20030601 |
| Comparative study of donepezil and rivastigmine. | International journal of clinical practice 20030601 |
| A review of rivastigmine: a reversible cholinesterase inhibitor. | Clinical therapeutics 20030601 |
| Dementia. | Clinical evidence 20030601 |
| [Current therapy of patients with dementia]. | MMW Fortschritte der Medizin 20030526 |
| Surprising discovery with Alzheimer's medication. | Drug discovery today 20030501 |
| Efficacy, safety and cost of new drugs acting on the central nervous system. | European journal of clinical pharmacology 20030501 |
| [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. | Nederlands tijdschrift voor geneeskunde 20030405 |
| [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. | Nederlands tijdschrift voor geneeskunde 20030405 |
| Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. | Acta neurologica Scandinavica 20030401 |
| [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. | Fortschritte der Neurologie-Psychiatrie 20030401 |
| Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. | International clinical psychopharmacology 20030301 |
| [Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period]. | Revista de neurologia 20030301 |
| Rivastigmine in the treatment of alcohol-induced persisting dementia. | The West Indian medical journal 20030301 |
| Age-related mild cognitive deficit: a ready-to-use concept? | Dialogues in clinical neuroscience 20030301 |
| The evaluation of cognitive function in the dementias: methodological and regulatory considerations. | Dialogues in clinical neuroscience 20030301 |
| Treatment of cognitive impairment in Alzheimer's disease. | Dialogues in clinical neuroscience 20030301 |
| Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. | Neuroscience letters 20030227 |
| Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205 |
| Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease. | Journal of the neurological sciences 20030115 |
| No additional benefit of HRT on response to rivastigmine in menopausal women with AD. | Neurology 20030114 |
| [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. | Nederlands tijdschrift voor geneeskunde 20030104 |
| Comparative study of donepezil and rivastigmine. | International journal of clinical practice 20030101 |
| Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20030101 |
| Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20030101 |
| The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease. | Gerontology 20030101 |
| Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. | Current medical research and opinion 20030101 |
| Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. | Alzheimer disease and associated disorders 20030101 |
| Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. | Phytomedicine : international journal of phytotherapy and phytopharmacology 20030101 |
| Advances in the pharmacological management of Parkinson disease. | Journal of neural transmission. Supplementum 20030101 |
| Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. | Current medical research and opinion 20030101 |
| Cholinesterase inhibitors for dementia with Lewy bodies. | The Cochrane database of systematic reviews 20030101 |
| Current treatments for Alzheimer's disease: cholinesterase inhibitors. | The Journal of clinical psychiatry 20030101 |
| M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. | Journal of molecular neuroscience : MN 20030101 |
| Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. | CNS drugs 20030101 |
| Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. | Acta biologica Hungarica 20030101 |
| Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. | American journal of Alzheimer's disease and other dementias 20030101 |
| The pharmacist's role in managing patients with Alzheimer's disease. | Journal of the American Pharmacists Association : JAPhA 20030101 |
| [Mechanisms of action of Alzheimer medications]. | Duodecim; laaketieteellinen aikakauskirja 20030101 |
| Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. | Clinical neuropharmacology 20030101 |
| Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis. | BMC geriatrics 20030101 |
| Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. | Current medical research and opinion 20030101 |
| No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment. | Current medical research and opinion 20030101 |
| Rivastigmine in vascular dementia. | International psychogeriatrics 20030101 |
| [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office]. | Fortschritte der Medizin. Originalien 20021205 |
| Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. | Journal of neurology, neurosurgery, and psychiatry 20021201 |
| Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. | Journal of clinical psychopharmacology 20021201 |
| Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. | International journal of clinical practice 20021201 |
| [Ethical aspects of anti-Alzheimer drugs: experiences of caregivers]. | Tijdschrift voor gerontologie en geriatrie 20021201 |
| Objective markers of drug effects on brain function from recordings of scalp potential in healthy volunteers. | Dialogues in clinical neuroscience 20021201 |
| Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs. | Dialogues in clinical neuroscience 20021201 |
| Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. | European journal of pharmacology 20021129 |
| Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. | Journal of medicinal chemistry 20021121 |
| Rivastigmine in subcortical vascular dementia: an open 22-month study. | Journal of the neurological sciences 20021115 |
| [Treatment of Alzheimer's disease]. | Revista de neurologia 20021101 |
| [Rivastigmine: a review of its clinical effectiveness]. | Revista de neurologia 20021101 |
| Rivastigmine in the treatment of Huntington's disease. | European journal of neurology 20021101 |
| Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20021101 |
| Responses to donepezil in Alzheimer's disease and Parkinson's disease. | Annals of the New York Academy of Sciences 20021101 |
| [Anti-dementia drugs for Alzheimer disease in present and future]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20021101 |
| Fatal aspiration pneumonia during transition from donepezil to rivastigmine. | The Annals of pharmacotherapy 20021001 |
| The impact of journal advertisements on prescribers of cholinesterase inhibitors. | International journal of geriatric psychiatry 20021001 |
| Cognitive pharmacotherapy of Alzheimer's disease and other dementias. | Canadian journal of psychiatry. Revue canadienne de psychiatrie 20021001 |
| [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease]. | Revue neurologique 20020901 |
| Electroconvulsive therapy in a patient receiving rivastigmine. | The journal of ECT 20020901 |
| Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20020901 |
| Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. | Neurology 20020827 |
| Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. | Journal of medicinal chemistry 20020815 |
| Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. | Neurology 20020813 |
| Clinical use of cholinomimetic agents: a review. | The Journal of head trauma rehabilitation 20020801 |
| SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. | The Journal of pharmacology and experimental therapeutics 20020801 |
| Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20020801 |
| Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. | Journal of neural transmission (Vienna, Austria : 1996) 20020701 |
| Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. | Journal of neural transmission (Vienna, Austria : 1996) 20020701 |
| Medical treatment of Alzheimer's disease: past, present, and future. | Medicine and health, Rhode Island 20020701 |
| Guidelines for managing Alzheimer's disease: Part II. Treatment. | American family physician 20020615 |
| Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. | Clinical therapeutics 20020601 |
| [Nicotinic Receptor, galantamine and Alzheimer disease]. | Revista de neurologia 20020601 |
| The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. | International journal of clinical practice. Supplement 20020601 |
| Do cholinesterase inhibitors slow progression of Alzheimer's disease? | International journal of clinical practice. Supplement 20020601 |
| The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. | International journal of clinical practice. Supplement 20020601 |
| Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. | International journal of clinical practice. Supplement 20020601 |
| Switching cholinesterase inhibitors in patients with Alzheimer's disease. | International journal of clinical practice. Supplement 20020601 |
| Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease. | International psychogeriatrics 20020601 |
| [Dementing disorders. What benefits do the new anti-dementia drugs have?]. | MMW Fortschritte der Medizin 20020506 |
| The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. | Molecular pharmacology 20020501 |
| Prolonged QT interval with rivastigmine. | The British journal of psychiatry : the journal of mental science 20020501 |
| Electrocardiographic effects of rivastigmine. | Journal of clinical pharmacology 20020501 |
| Pharmacologic treatments of dementia. | The Medical clinics of North America 20020501 |
| Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? | Progress in neuro-psychopharmacology & biological psychiatry 20020501 |
| Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. | Progress in neuro-psychopharmacology & biological psychiatry 20020501 |
| A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. | International journal of geriatric psychiatry 20020401 |
| The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. | International journal of clinical practice 20020401 |
| Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. | Biochemistry 20020319 |
| [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. | Nederlands tijdschrift voor geneeskunde 20020309 |
| Rivastigmine in outpatient services: experience of 114 neurologists in Austria. | International clinical psychopharmacology 20020301 |
| Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it? | International journal of geriatric psychiatry 20020301 |
| Understanding changes in cholinergic function: implications for treating dementia. | The Journal of clinical psychiatry 20020301 |
| Rivastigmin and impaired motor function. | Pharmacopsychiatry 20020301 |
| [Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report]. | Arquivos de neuro-psiquiatria 20020301 |
| Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease. | European journal of medicinal chemistry 20020201 |
| An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. | Medical science monitor : international medical journal of experimental and clinical research 20020201 |
| Cholinergic drugs in pharmacotherapy of Alzheimer's disease. | Mini reviews in medicinal chemistry 20020201 |
| Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. | Neuroreport 20020121 |
| [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. | Nederlands tijdschrift voor geneeskunde 20020105 |
| Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. | European neurology 20020101 |
| Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. | Dementia and geriatric cognitive disorders 20020101 |
| In vitro toxicity of rivastigmine and donepezil in cells of epithelial origin. | Ophthalmic research 20020101 |
| Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. | Clinical pharmacokinetics 20020101 |
| Cutaneous drug reaction case reports: from the world literature. | American journal of clinical dermatology 20020101 |
| Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. | Clinical neuropharmacology 20020101 |
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. | Current medical research and opinion 20020101 |
| Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. | Current medical research and opinion 20020101 |
| Cholinergic medication for neuroleptic-induced tardive dyskinesia. | The Cochrane database of systematic reviews 20020101 |
| Galantamine for Alzheimer's disease. | The Cochrane database of systematic reviews 20020101 |
| Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. | Clinical pharmacokinetics 20020101 |
| Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine? | International journal of clinical practice 20020101 |
| A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. | International journal of clinical practice 20020101 |
| Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. | Neuroscience 20020101 |
| AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. | Journal of molecular neuroscience : MN 20020101 |
| Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. | Current medical research and opinion 20020101 |
| Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. | International journal of technology assessment in health care 20020101 |
| Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. | Current medical research and opinion 20020101 |
| The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. | Clinical and experimental hypertension (New York, N.Y. : 1993) 20020101 |
| Impact of muscarinic agonists for successful therapy of Alzheimer's disease. | Journal of neural transmission. Supplementum 20020101 |
| Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. | Clinical neuropharmacology 20020101 |
| The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. | International psychogeriatrics 20020101 |
| The ABC of Alzheimer's disease: behavioral symptoms and their treatment. | International psychogeriatrics 20020101 |
| Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. | International psychogeriatrics 20020101 |
| A clinical overview of cholinesterase inhibitors in Alzheimer's disease. | International psychogeriatrics 20020101 |
| [Acetylcholinesterase inhibitors--beyond Alzheimer's disease]. | Psychiatria polska 20020101 |
| Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine. | European journal of pharmacology 20011214 |
| [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]. | MMW Fortschritte der Medizin 20011213 |
| [Perspectives for drug treatment in Alzheimer's disease]. | Annales de medecine interne 20011201 |
| [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. | Fortschritte der Medizin. Originalien 20011129 |
| Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. | Mechanisms of ageing and development 20011101 |
| Erythematous maculopapular eruption due to rivastigmine therapy. | The American journal of medicine 20011101 |
| Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. | Movement disorders : official journal of the Movement Disorder Society 20011101 |
| Adverse reactions to rivastigmine in three cases of dementia. | The Australian and New Zealand journal of psychiatry 20011001 |
| Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. | Journal of clinical pharmacology 20011001 |
| Acetylcholinesterase inhibitor SDZ ENA 713 (Rivastigmine) increases brain pyrrolidone carboxyl peptidase activity. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20011001 |
| Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. | The international journal of neuropsychopharmacology 20010901 |
| [Anticholinesterase agents in Alzheimer's disease]. | Revue medicale de Bruxelles 20010901 |
| Dementia in Parkinson's disease. | Journal of neurology 20010901 |
| Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. | International psychogeriatrics 20010901 |
| Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. | Mini reviews in medicinal chemistry 20010901 |
| Use of acetylcholinesterase inhibitors in Alzheimer's disease. | Expert review of neurotherapeutics 20010901 |
| Therapeutic approaches to age-associated neurocognitive disorders. | Dialogues in clinical neuroscience 20010901 |
| Brain aging research at the close of the 20th century: from bench to bedside. | Dialogues in clinical neuroscience 20010901 |
| Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. | Brain research 20010810 |
| Medications for the treatment of Alzheimer's disease. | The Journal of the Oklahoma State Medical Association 20010801 |
| Maintaining cognitive function in Alzheimer disease: how effective are current treatments? | Alzheimer disease and associated disorders 20010801 |
| Maintaining functional and behavioral abilities in Alzheimer disease. | Alzheimer disease and associated disorders 20010801 |
| Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. | European journal of neurology 20010701 |
| Use of cholinesterase inhibitors for treatment of Alzheimer disease. | Cleveland Clinic journal of medicine 20010701 |
| Featured CME topic: dementia. Medication update. | Southern medical journal 20010701 |
| Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. | Annals of the New York Academy of Sciences 20010601 |
| Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. | International psychogeriatrics 20010601 |
| Rivastagmine-induced agitation following transient recollection of autobiographical memory. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20010601 |
| Alzheimer's disease and related disorders. | The Medical clinics of North America 20010501 |
| Is it Alzheimer's? Neuropsychological testing helps to clarify diagnostic puzzle. | Geriatrics 20010401 |
| Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. | Expert opinion on pharmacotherapy 20010401 |
| Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. | Farmaco (Societa chimica italiana : 1989) 20010401 |
| Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. | Archives of neurology 20010301 |
| Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine. | Age and ageing 20010301 |
| [Evaluation of the therapeutic effects in individual patients with Alzheimer disease]. | Nederlands tijdschrift voor geneeskunde 20010224 |
| Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor. | Journal of clinical psychopharmacology 20010201 |
| Brief review: rivastigmine, a second cholinesterase inhibitor. | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20010201 |
| Cholinesterase inhibitors for Alzheimer's disease. | Drugs 20010101 |
| Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. | Health technology assessment (Winchester, England) 20010101 |
| Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. | Clinical neuropharmacology 20010101 |
| Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. | PharmacoEconomics 20010101 |
| Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. | Neuropsychobiology 20010101 |
| Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. | Clinical therapeutics 20010101 |
| Switching previous therapies for Alzheimer's disease to galantamine. | Clinical therapeutics 20010101 |
| Pharmacokinetic rationale for switching from donepezil to galantamine. | Clinical therapeutics 20010101 |
| [Current strategies of pathogenetic therapy of Alzheimer's disease]. | Vestnik Rossiiskoi akademii meditsinskikh nauk 20010101 |
| Rivastigmine in the treatment of Alzheimer's disease. | European neurology 20010101 |
| Galantamine for Alzheimer's disease. | The Cochrane database of systematic reviews 20010101 |
| [Risperidone in the ambulatory treatment of behavior disorders in demented patients of Alzheimer's type: a retrospective analysis]. | Psychiatria polska 20010101 |
| A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. | Current medical research and opinion 20010101 |
| Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials. | Neurologia i neurochirurgia polska 20010101 |
| Drugs used for cognitive symptoms of Alzheimer's disease. | Perspectives in psychiatric care 20010101 |
| Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. | Japanese journal of pharmacology 20001001 |
| Relation between cholinesterase inhibitor and Pisa syndrome. | Lancet (London, England) 20000624 |
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. | BMJ (Clinical research ed.) 19990306 |
| Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. | Behavioural neurology 19980101 |